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The mitochondrial proteome is composed of both mitochondrial and nuclear encoded 
proteins. Restructuration of mitochondrial proteome is often required upon on change in 
nutrient availabilities and stress conditions. To facilitate this process, the nuclear and 
mitochondrial genome must coordinate their protein expression in a well-concerted 
manner. Additional factors are present to mediate the coordination. These factors are 
diverse in function ranging from energy sensing to translation of the specific nuclear 
encoded mitochondrial proteins.  
Clu is a well-conserved cytosolic protein, however its molecular function remains 
unknown. A small fraction of Clu is observed outside of mitochondria in Drosophila. 
Clu mutant of multicellular organisms display phenotypes of growth defect, failure to 
respond to stress and early death. However these phenotypes are absent from single 
cellular organisms. Nevertheless, all Clu mutants have clustered mitochondria and this 
leads to the speculation that CLUH and mitochondria are functionally closely related. 
In this study, we analysed the genes that coregulate with human and murine 
CLUH/Cluh, respectively, and identified two main clusters of genes: nuclear encoded 
mitochondrial genes and cytosolic translation related genes. After this, we identified the 
molecular function of human CLUH as an mRNA binding protein by using crosslinking 
immunoprecipitation (CLIP). By comparing the mRNAs enriched by CLUH to control 
IgG, we discovered that CLUH binds specifically to mRNAs of nuclear encoded 
mitochondrial proteins (NEMP). Among the mRNAs bound by CLUH, we found 
enrichments for genes involved in branched-chain amino acid degradation, 
mitochondrial dysfunction, TCA cycle, oxidative phosphorylation and fatty acid α-
oxidation. Subsequently, we showed that CLUH is a positive translation regulator of its 
target mRNAs, because in the absence of CLUH, translation of its target mRNAs 
appeared to be reduced. However, general translation was not affected in the absence of 
CLUH. Furthermore, we found a reduction of CLUH in PGC-1α null mouse embryonic 
fibroblasts (MEFs), which indicates that CLUH expression might be under the 
transcriptional control of PGC-1α. Together, we conclude that CLUH might be 
important for the biogenesis of its target proteins under influence of cellular metabolism. 
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1.1 Mitochondria  
1.1.1 Origin of mitochondria  
 
Mitochondria were first observed and described with various names as early as the 
1800s, when the German histologist Richard Altmann proposed that this cellular 
granule to be autonomous and forming colonies in the cytoplasm in his book “Die 
Elementarorganismen”. It took another seven decades to discover the existence of DNA 
in mitochondria (mtDNA) (Nass and Nass 1963) and another two decades to find the 
evidence that mtDNA is not originated from the host genome via invagination during 
evolution (Farrelly and Butow 1983). Altogether, these evidences strongly support the 
endosymbiotic theory, which explains that mitochondria arose as a result of either a 
singular or multiple events of fusion of α-proteobacterium and eukaryotic progenitor 
(Macklin 1927). To many respects, these original endosymbiotic events mark the rise of 
the eukaryotes since a nucleus-bearing living eukaryotes completely devoid of 
mitochondria has yet to be discovered (Williams, Hirt et al. 2002; Chan, Slotboom et al. 
2005; van der Giezen and Tovar 2005). This cooperation allowed the expansion of 
eukaryotes due to the acquisition of the super energy-producing “plant”. Along the 
course of evolution, mitochondria have lost and transferred most of their genes to the 
nucleus (Adams and Palmer 2003) and mitochondria only retain a skeletal genome, 
relatively small compared to the bacterial ancestor and encoding only components of the 
mitochondrial translation machinery and of the oxidative phosphorylation (OXPHOS). 
 
1.1.2 Mitochondrial genome 
 
In human, the circular mtDNA is composed of only 16,569 base pairs. Despite the 
comparatively small size of this genome (only 1/3000th of the size of our smallest 
chromosome 21), mutation, deletion and depletion of mtDNA can lead to severe 
diseases. Human mitochondrial genome encodes for 37 genes including 22 tRNAs, two 
rRNAs and 13 polypeptides. The mtDNA is a double stranded molecule with cytosine-
rich light strand and a guanine-rich heavy strand (Anderson, Bankier et al. 1981).  
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Unlike the nuclear genome, multiple copies of mtDNAs can be found per 
mitochondrion as a result of regulated replication and this condition is referred as 
polyploidy. Despite the existence of DNA repair systems in plant and mammalian 
mitochondria (Boesch, Ibrahim et al. 2009; Boesch, Ibrahim et al. 2010), high rate of 
mutations still occurs and leads to heteroplasmy (Dianov, Souza-Pinto et al. 2001). In 
such case, mitochondria will host a heterogeneous mix of healthy and mutated genomes, 
the specific threshold at which mutated genome exceeds the wildtype genome can 
determine the onset of mitochondrial dysfunction (Wong 2007). Since mtDNAs are 
maternally inherited, this condition can be prevented through three parents in vitro 
fertilisation or mitochondrial replacement therapy, in which the resulting embryo 
contains the nuclear genetic material from two parents and mitochondrial genetic 
material from a healthy female donor (Klitzman, Toynbee et al. 2015).   
mtDNA is not naked, instead, multiple copies are packed by proteins and form nucleoid 
structures. This is in contrast to the nucleosome, where DNA wraps around the histone 
complex (Table 1) (Taylor and Turnbull 2005). Nucleoids are not free floating in the 
matrix but associate with the inner mitochondrial membrane (Wang and Bogenhagen 
2006; Holt, He et al. 2007). It is estimated that one nucleoid is capable of packing 5-7 
copies of the mtDNA (Iborra, Kimura et al. 2004). The exact composition of the 
nucleoids as well as the very nature of the molecule or complex tethering the mtDNA to 
the  mitochondrial inner membrane (IM) is still debated today (Kukat and Larsson ; 
Holt, He et al. 2007). The mtDNA copy number is subjected to tight regulation and 
failures to maintain the desired copy numbers lead to mtDNA depletion syndromes 
(MDS) (Macmillan and Shoubridge 1996; Choi, Kim et al. 2001; Blokhin, Vyshkina et 
al. 2008; Xing, Chen et al. 2008). MDS can be caused by mutations in both nuclear and 
mitochondrial genomes.  
Mitochondria are not only involved in the aforementioned diseases but also have a 
possible role in the aging process. Indeed, the original Harman theory of aging 
postulated that the accumulation of free radical damage over time ultimately led to 
cellular aging (Harman 1956). While this theory became widely accepted, it has been 
challenged by work done on the mutator mice, in this model, aging and mutation load 
were studied in mice deficient in mtDNA repair mechanisms but free radicals did not 
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correlate with accumulation of mutations and aging (Trifunovic, Wredenberg et al. 
2004).  
 




1.1.3 Brief introduction of the mitochondrial function 
 
Mitochondria are present in virtually all eukaryotic cells, with the notable exception of 
the erythrocytes, which are also devoid of nuclei, Golgi and endoplasmic reticulum in 
mammals. They constantly undergo fusion and fission events to assist in content 
exchanges and protect against stresses (Chan 2006). Mitochondria are 
compartmentalised by two membranes composed of phospholipid bilayers (Figure 1): 
the two membranes, namely the outer membrane (OM) and inner membrane are 
separated by the intermembrane space (IMS) while the compartment enclosed by IM is 
referred as the matrix. IM infolds into the matrix and forms cristae. Cristae structure 
alters according to the respiratory state of mitochondria and apoptosis (Hackenbrock 
1966; Scorrano, Ashiya et al. 2002; Frezza, Cipolat et al. 2006; Yamaguchi, Lartigue et 
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al. 2008). The OM is not considered as a potent membrane barrier due to the presence of 
a large, pore forming complex, the porin or voltage dependant anion channel (VDAC) 
which allows for the passive diffusion of molecules under 5000 kDa (Scheffler 2007). 
In contrast, the IM harbors many carriers and uniporters that selectively transport 
molecules such as ADP/ATP, Pi, NAD+/NADH, H+, Ca2+, Fe2+, Cu+, Zn2+, pyruvate, 
amino acids and many more (Kunji 2004). It is estimated that 39 carriers with different 
functions are present in the IM. Moreover, it also provides sites for the complexes of 
OXPHOS for ATP production.  
The function of mitochondrial proteins are extremely diverse, including ATP production, 
type II fatty acid synthesis, fatty acids and amino acids oxidation, pyrimidine 
biosynthesis, calcium homeostasis, iron-sulfur cluster synthesis, urea cycle, ROS and 
heat production, apoptosis and viral defense response. Here I will only focus on 
pathways involved in direct ATP production (Scheffler 2007). 
 
Figure 1: Mitochondrial compartment and proteome distribution (A) Schematic illustration 
of a mitochondrion. (B) Estimation of protein distribution across the compartments of 




Tricarboxylic acid cycle or TCA cycle is central for metabolism. It is in this pathway 
that the substrates derived from carbohydrates, fats and proteins are interconnected. 
TCA cycle utilises acetyl-CoA to form diverse metabolic chemicals, such as NADH, 
FADH2, ATP (GTP), ubiquinone and other precursors. NADH and FADH2 are then 
conveyed to the OXPHOS to create a proton gradient that generates ATP. The cycle 
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itself is generally controlled by the end product of each reaction. All protein 
components of the TCA cycle are encoded by the nuclear genome.  
The TCA cycle provides many metabolites and precursors for the cellular activities. 
Oxaloacetate and α-ketoglutarate can be taken from the cycle by cataplerotic reaction to 
form amino acids, or they can be put back directly into the cycle by anaplerotic 
reactions. Glutamine, when provided externally, is transported into the matrix and 
converted to glutamate and subsequently α-ketoglutarate, and enters the TCA cycle. At 
the end of TCA cycle, oxaloacetate can be taken to yield aspartate and asparagine or 
alternatively, oxaloacetate is redirected to gluconeogenesis. Acetyl-CoA is essential to 
form fatty acid, ketone bodies, and cholesterol, while acetyl-CoA can be replenished 
back from these metabolites. The cycle is also important in providing acetyl-group 
required for post-translational modification. Succinyl-CoA from TCA cycle can 
combine with glycine to form δ-aminolevulinic acid (ALA). This is the initial reaction 




OXPHOS is a metabolic process where ATP is produced from ADP and Pi by 
transfering electrons from NADH and FADH2 to O2. This process requires the 
participation of the electron transport chain (ETC) and ATP Synthase (complex V), both 
are made up by nuclear and mitochondrial encoded proteins (Figure 2). The ETC is 
composed of four complexes, collectively known as oxidoreductases, which couple 
electron transport with translocation of protons across the IM to IMS (apart from 
complex II, which does not possess proton pumping activity).  
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Figure 2: Distribution of nuclear encoded (nDNA, blue, except for DHOD) and 
mitochondrial encoded protein (other colours) in the OXPHOS in human (Schon, 
DiMauro et al. 2012) 
 
Complex I, also known as NADH-ubiquinone oxidoreductase is the largest in size with 
45 core subunits and an enormous amount of assembly factors, it forms an L shape 
complex in the IM (Diaz, Kotarsky et al. 2011). In this step, the electron carrier NADH 
generated from TCA cycle is oxidized to NAD+, generating four protons across the 
membrane. It is also the major source of reactive oxygen species inside mitochondria 
(Murphy 2009).  
Complex II (succinate:ubiquinoneoxidoreductase, or succinate dehydrogenase) is the 
simplest complex of the ETC with only four subunits which are exclusively nuclear 
encoded in mammals. The two largest subunits SDHA and SDHB locate on the 
peripheral of the IM. Complex II also takes part in TCA cycle to facilitate conversion of 
succinate to fumarate. The resulting electrons are then transferred directly through 
complex II to ubiquinone in the ETC. 
Complex III or ubiquinone-cytochrome c oxidoreductase, also known as cytochrome c 
reductase is another major source of reactive oxygen species production in mitochondria. 
Mammalian complex III consists of 11 subunits, however only three are functionally 
important since they are the only components of the bacterial counterparts, they are: 
cytochrome b (mtDNA encoded) cytochrome C1 and the Rieske iron-sulfur protein.  
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Complex IV, the cytochrome c oxidase, catalyses the final electron transfers to H2O 
with O2 as the electron acceptor. It contains 13 subunits, three of the largest subunits are 
encoded by the mitochondrial genome (COX I, II and III) however around 30 factors 
are required for the assembly of this complex.  
Complex V or ATP synthase utilises the proton gradient generated in the IMS to 
catalyse the phosphorylation of ADP to ATP. Complex V is a lollipop-like structure 
with a “head” facing the matrix and its “neck”inserted in the IM. The “head” is named 
F1-ATP synthase and is made up of nine subunits: 3α, 3β, 1γ, 1δ, and 1ε. The neck is F0-
synthase and consists of a subunit c-ring and a, b, d, F6 and the oligomycin sensitivity-
conferring protein (OSCP). There are also other subunits associated with F0: e, f, g and 
A6L. Two of the F0 subunits are encoded by mtDNA: ATP6 (a) and ATP8 (A6L) 
(Anderson, Bankier et al. 1981) (Jonckheere, Smeitink et al. 2012) 
Complexes I, III and IV are found to form specific respirasome (complex I + III + IV) 
and/or supercomplexes (complex I + III, complex III + IV) (Dudkina, Sunderhaus et al. 
2008; Lapuente-Brun, Moreno-Loshuertos et al. 2013) while ATP synthase can 
dimerise and form long oligomeric chains. Moreover because of such formation, 
assembly of one complex can affect the other: for instance, complex I disassembles in 
the absence of complex III and IV (Scheffler 2007). 
 
1.2 Biogenesis of nuclear encoded mitochondrial proteins 
 
1.2.1 Coordination between nucleus and mitochondria to ensure appropriate 
protein expression 
 
Because of the coexistence of nuclear and mitochondrial genomes, concerted 
coordination is required for the expression of nuclear and mitochondrial encoded 
proteins. For example, the OXPHOS houses nearly 80 subunits with only 13 being 
encoded in the mitochondria (Figure 2A). It is estimated that about 1500 proteins are 
present in a given mitochondrion depending on the sample type, purification method 
and detection sensitivity (Calvo and Mootha 2010). Moreover, mitochondrial protein 
expression pattern is tightly controlled in specific cell types depending on the metabolic 
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demand (Figure 3A and B) (Calvo and Mootha 2010) Therefore, mitochondria and 




Figure 3: Mitochondrial proteome. (A) Mitochondrial abundance in tissues (B) Expression 
profile of the subunit of protein complexes in different tissues. Black indicates lack of detection 
whereas red is the level of abundance (Calvo and Mootha 2010). 
 
There is an enormous amount of factors involved in the cross-talk processes, residing or 
shuttling in between mitochondria, cytosol and the nucleus. If we take the example of 
ATP production, mitochondrial function is monitored in terms of metabolites (pyruvate, 
NADH and ATP) derived from glycolysis, TCA cycle and the OXPHOS, respectively. 
During fasting, in the liver, the increase of pyruvate is coupled with an increased ratio 
of NAD+: NADH, this subsequently leads to post-translational upregulation of Sirt1 (a 
NAD+ dependent deacetylase) in the nucleus (Rodgers, Lerin et al. 2005). In the 
meantime the ratio of AMP: ATP or ADP levels are monitored by AMP-acivated 
protein kinase (AMPK) in the cytosol. When AMP:ATP ratio increases, AMPK is 
phosphorylated and induces a cascade of changes (Mihaylova and Shaw 2011). AMPK 
phosphorylation and Sirt1 activation can lead to the upregulation of the master 
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transcriptional coactivator: peroxisome proliferators-activated receptor γ coactivator 1-
alpha (PGC-1α). Consequently, this triggers the transcription induction of NEMPs such 
as OXPHOS components (Puigserver, Wu et al. 1998; Nunnari and Suomalainen 2012). 
 
1.2.2 Regulation of nuclear encoded mitochondrial proteins  
 
PGC-1 was first identified as a cold inducible activator of uncoupling protein 1 (UCP-1), 
which is important for energy dissipation in the brown fat cells. Under normal condition, 
PGC-1 is expressed in the heart, kidney, brown fat and brain but at very low level in 
lung, muscle, liver, white fat, testis and spleen (Puigserver, Wu et al. 1998). PGC-1 
expression can be induced in the liver under fasting or diabetic condition (Yoon, 
Puigserver et al. 2001) or cold shock in brown fat and slow-twitch skeletal muscles 
(Puigserver, Wu et al. 1998). It interacts with various transcription factor partners, to 
name a few: peroxisome proliferator-activated receptor γ (PPARγ), thyroid hormone 
receptor (TR), retinoic acid receptor (RA), estrogen receptors (Puigserver, Wu et al. 
1998), PPARα (Vega, Huss et al. 2000), PPARβ (Wang, Lee et al. 2003), nuclear 
respiratory factor 1 and 2 (Wu, Puigserver et al. 1999) and estrogen-related receptors α 
(ERRα) (Huss, Kopp et al. 2002; Schreiber, Knutti et al. 2003). Depending on the 
combination of the complexes, different set of genes can be activated: ERRα, PPARα 
PPARγ and NRF-1, which regulates the transcription of genes involved in 
mitochondrial fatty acid beta-oxidation and oxidative phosphorylation and mtDNA 
transactions (Scarpulla 2002). All nuclear encoded proteins are translated in the cytosol, 
however whether they are localised to mitochondria before or after translation is still 
under debate, this is especially true for the NEMPs.  
 
1.2.3 Mitochondrial post-translational versus co-translational protein targeting 
and import. 
 
Two main mitochondrial protein targeting/import models exist (Figure 4): post-
translational (Neupert and Herrmann 2007) and co-translational (MacKenzie and Payne 
2007). In the former, the NEMPs are translated in the cytosol, unfolded by chaperons, 
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imported via the translocases of the outer membrane (TOM complex) and sorted to their 
respective destination. This mode of protein localisation and import to mitochondria 
relies on the presence of mitochondrial targeting signals which is also a determinant for 
mitochondrial protein sorting after passing TOM (Chacinska, Koehler et al. 2009). The 
mRNA, in this case, does not participate in the event of protein targeting to 
mitochondria. Evidences supporting post-translational import include: (1) Many 
precursor proteins can be made and imported into isolated mitochondria by in vitro 
protein import assays (Harmey, Hallermayer et al. 1977). (2) Not all nuclear encoded 
mRNAs are associated with mitochondria, many are present in the cytosol and associate 
with free polysomes (Marc, Margeot et al. 2002). (3) The order of protein translation 
dictates that all proteins have to be translocated from the N-terminal in co-translational 
model. This is challenged by protein with a non-canonical C-terminal targeting and 
sorting sequence.  
On the other hand, the co-translational model suggests that localisation of mRNAs to 
the vicinity of mitochondria prior to their translation. After translation, the peptide 
emerges from the ribosome exit tunnel of the ribosome and is “captured” and “pulled” 
through the TOM complex. Therefore, in this case, mRNA targeting to mitochondria 
precedes protein localisation and is important for mitochondrial biogenesis. This model 
is supported by increasing evidence of (1) A fraction of NEMP mRNAs localise in the 
vicinity of mitochondria (Marc, Margeot et al. 2002). (2) Mitochondrial targeting 
sequence is not necessary to be a determinant for mitochondrial localisation of some 
proteins (Mukhopadhyay, Ni et al. 2004). In fact mRNA localisation is not only 
observed in mitochondria but also in peroxisomes and ER (Marc, Margeot et al. 2002; 
Pyhtila, Zheng et al. 2008; Zipor, Haim-Vilmovsky et al. 2009). When translation 
elongation is inhibited, ribosomes accumulate on the surface of mitochondria. Moreover 
the signal peptides are believed to be translated during mRNA transport and acting as a 
guide for path finding to the proper destination. Tom20, part of the TOM complex can 
mediate localisation of some mRNAs (Eliyahu, Pnueli et al. 2010; Kilchert and Spang 
2011). It is, of course, possible that in nature, the two models coexist. Localisation of 
mRNAs and localisation of mRNA to mitochondria will be discussed further in the next 
chapter. 
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Figure 4: Protein targeting models. In post-translational model, protein targeting relies on the 
presence of mitochondrial targeting signals whereas co-translational model requires the 
targeting of mRNAs to the vicinity of mitochondria followed by localised translation. 
 
1.2.4 The targeting and sorting sequence of mitochondrial proteins 
 
The function of a protein dictates its conformation and location. Newly synthesised 
proteins must be sorted and folded correctly by the virtue of the other proteins as well as 
the intrinsic targeting signal that the new proteins possess (Table 2) (Chacinska, 
Koehler et al. 2009). 
The best-known mitochondrial targeting sequence (MTS) is the cleavable amphipathic 
α-helix presequence at the N-terminal of a protein. This sequence can be up to 100 
amino acids and is cleaved off by the matrix processing peptidase (MPP) after import. 
Therefore, it is used by most of matrix proteins. For some IM proteins, a hydrophobic 
segment is present after the amphipathic α-helix. This segment can halt further 
translocation of the preprotein and remains as a part of the mature protein. In contrast to 
some IMS proteins, the mature protein is formed after translocating through the IM, 
followed by cleavage by MPP in the matrix as well as cleavage of the hydrophobic IM 
insertion by inner membrane peptidase (Table 2 A). 
None of the OM proteins possesses any of the aforementioned features mainly because 
they do not translocate the IM and reach the matrix, however large number of IM 
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proteins and IMS proteins do not have any cleavable targeting sequence. The targeting 
sequence of OM proteins can be found at the N-terminus, internal or the C-terminus 
(Table 2B) based on the topology of the proteins: α-helices with N-terminal, internal 
domain or C-terminal insertion into the membrane or β-barrel conformation.The IM 
contains many multi-spanning transmembrane metabolite carriers that harbor multiple 
intrinsic α-helix targeting signals. A number of IM proteins contain a presequence like 
structure with positively charged α-helices after hydrophobic stretch (Table 2B). IMS 
proteins embody mitochondrial intermembrane space signal (MISS) with a cysteine 
residue that can be recognised and sorted (Table 2C) (Chacinska, Koehler et al. 2009). 
 
Table 2: Targeting and sorting signals present in nuclear encoded mitochondrial proteins 
(Chacinska, Koehler et al. 2009). 
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1.2.5 TOM and the sorting machinery 
 
TOM complex is the entry gate of almost all nuclear encoded mitochondrial proteins. 
TOM is composed of 7 subunits: two receptors TOM70 and TOM20 and the general 
import core TOM40 (forms oligomeric β-barrel), TOM22, TOM7, TOM6 and TOM5 
(Figure5 ) (Model, Meisinger et al. 2008). TOM20 and TOM70 are the initial contact 
sites for preprotein with presequence and IM proteins, respectively. They are also 
important for the localisation of mRNAs in co-translational import model together with 
TOM7 (Eliyahu, Pnueli et al. 2010; Gadir, Haim-Vilmovsky et al. 2011). After the 
initial contact, the preproteins are then transferred to TOM22, TOM5, translocated 
through TOM40 to bind to the IMS domain of TOM22. From this point onward, 
preproteins are sorted to OM via the SAM (sorting and assembly machinery), to the 
IMS via MIA (mitochondrial intermembrane space assembly), to the IM via TIM 22 
(transloase of the inner mitochondrial membrane) and to the matrix via TIM23 (Figure 
5). 
 
Figure 5: Mitochondrial protein sorting pathways. After entry through TOM, the precursor 
proteins are sorted into different compartments. OXA is the insertase of mitochondrial encoded 
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1.3 mRNA localisation 
 
1.3.1 mRNA localisation is an ubiquitous phenomenon 
 
mRNA localisation in the cell is evolutionarily conserved from single cell organism to 
multicellular systems and serves as a mean of stimuli-controlled local translation. This 
regulation ensures that the right amount of proteins can be made at the right time, in the 
right place with right conformation and post-translational modifications. In yeasts, to 
ensure that the daughter cells cannot switch mating types, ASH 1 mRNA is transported 
to the daughter bud via myosin and actin prior to fission (Long, Singer et al. 1997). 
Tightly controlled compartmentalisation of mRNAs is observed during early 
Drosophila embryogenesis (Lecuyer, Yoshida et al. 2007). The mRNA of cytoskeletal 
elements: actin, vimentin and tubulin have been shown to localise to cell extremities, 
perinuclear and peripheral cytoplasm, respectively in chicken embryonic myoblasts and 
fibroblasts (Lawrence and Singer 1986). In highly polarised and specialised cell types 
such as neurons, many different types of mRNAs are found to be localised to direct the 
growth of axons (Zivraj, Tung et al. 2010) and dendrites (Kleiman, Banker et al. 1990).  
Normally, functionally related mRNAs are bundled and translated coordinately and 
therefore can be efficiently controlled (Gerber, Herschlag et al. 2004; Keene 2007). This 
precise local translational control is favored over directly transporting protein, because 
(1) One mRNA can be translated to the exact desired amount of proteins according to 
demand. (2) Local translation provides rapid response to local demand when compared 
to protein localisation. (3) During protein transport, cellular stress could impose 
undesired damage to the protein. (4) For some hydrophobic membrane proteins, it can 
be energetically favorable to insert the protein while being translated to avoid 
misfolding and aggregation.  
mRNA localisation is different from transport and it can be seen as a final step 
following the transportation of mRNA. mRNA protein complexes (mRNPs) are 
composed of mRNA, mRNA binding proteins or other associating proteins and proteins 
that connect the mRNP complex to cytoskeleton via motor proteins (Gagnon and 
Mowry 2011). As soon as the mRNAs are transcribed and spliced, they are sorted 
according to their destination with different protein compositions (i.e. RNP granules). 
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These granules are distinct from both stress or P granules in composition and function 
even though, general translation is halted in all cases (Anderson and Kedersha 2006; 
Anderson and Kedersha 2009).  
Transport of mRNAs to their final destination is a result from two factors: the cis-acting 
RNA sequence and the trans-acting proteins (RNA binding proteins or RBP) that bind 
to the mRNAs.  
Cis-acting RNA sequences, also known as "zipcodes", lie within the mRNAs and dictate 
the direction of transport, they could be in the 3’-UTR (for example, ASH 1 and β-actin) 
(Bassell, Zhang et al. 1998; Chartrand, Meng et al. 1999), 5’-UTR (kor, mRNA of 
kappa opioid receptor) (Tsai, Bi et al. 2007), and even within the protein coding 
sequence (mRNA target of FMRP, loss of function mutation causes fragile X syndrome) 
(Darnell, Van Driesche et al. 2011). The coding message can be hidden either in a short 
or long stretch of nucleotides or multiple units scattered through the sequence. It can 
also be coded in its secondary structure. Different signals may even be employed at 
different stages of mRNA transport and localisation (Hervé, Mickleburgh et al. 2004). 
One representative of such complexity is the localisation of the mRNA of myelin basic 
protein (MBP) to myelin: it is firstly transported to the oligodendrocytes via a 21-
nucleotide sequence in the 3´-UTR (RNA transport signal), followed by localisation to 
myelin compartment via a long stretch of nucleotides in 3´-UTR that forms a stable 
secondary structure (the RNA localisation region) (Ainger, Avossa et al. 1997). Another 
example is that the bicoid mRNA localisation to the anterior pole in Drosophila embryo 
requires two different cis-acting elements for early and late localisation and formation 
of double stranded helical structure to achieve the anchorage in the anterior cytoplasm 
(Ferrandon, Koch et al. 1997). 
Trans-acting proteins are the other factor that dictates the transport and localisation of 
mRNAs. They bind to the cis-acting elements of the mRNAs, their binding or 
association depends on the life cycle of an mRNA: transport, localisation or anchorage. 
In cultured HeLa cells, approximate 860 proteins have been identified as RNA binding 
proteins, the actual number, however might be even more due to the stringent threshold 
of the analysis (Castello, Fischer et al. 2012). To complicate the matters further, one 
RBP is able to bind to hundreds of different mRNAs (Gerber, Herschlag et al. 2004) and 
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one RNA can be bound by numerous RBPs. For example, Staufen recognises the loop 
structure formed by two strands of different RNAs in the zipcode, its target mRNAs 
include prospero and bicoid in flies. The association between Staufen and its target 
mRNAs is location specific: anterior to the anchoring of bicoid, and posterior to the 
localisation of oskar (St Johnston, Beuchle et al. 1991; Ferrandon, Koch et al. 1997). 
Therefore, it is reasonable to extrapolate that the RNA granules are extremly dynamic 
structures that change in time, space and cellular stresses. It is believed that during 
transport, mRNA translation is inhibited and mRNA is stabilised/protected and only 
become activated when reaching its destination (Abaza and Gebauer 2008; Besse and 
Ephrussi 2008).  
Proper localisation of mRNAs in either polarised or less polarised cells is an essential 
feature to determine the morphogenesis and development. However, mRNAs are also 
localised to different organelles (Weis, Schleiff et al. 2013). For example, the mRNAs 
for secretory, integral proteins and some cytosolic proteins are localised to the ER prior 
to complete translation, the signal recognition particle (SRP) pathway. After the release 
of mRNP into the cytosol, the complex is bound by ribosomes and a small length of 
polypeptide (signal peptide) is translated. Together this forms ribosome mRNA-nascent 
polypeptide complexes (RNCs) that can be recognised by the SRP. At the ER, SRP 
receptor recognises RNC-SRP, RNC stalks at the translocation channel and continues 
the translation while the nascent chain is “pulled” inside of the ER (Figure 6A) 
(Nicchitta, Lerner et al. 2005). However this classical co-translational model is also 
challenged by other models where the cis-acting element is important for localisation to 
the surface of ER instead of the SRP (Figure 6B). 
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Figure 6: mRNA localisation to the ER. (A) Three forms of mRNA localisation mediated by 
the signal peptide. (B) mRNA localisation imposed by the cis-acting element of the mRNA 
together with ribosomes (Weis, Schleiff et al. 2013). 
 
1.3.2 mRNA localisation to mitochondria 
 
This brings us to the question of whether a similar mRNA localisation pathway also 
occurs in the mitochondria. The vast majority of the work on mRNA localisation to 
mitochondria was carried out in yeast owing to ease in manipulation, however this is 
also observed in mammalian cells (Matsumoto, Uchiumi et al. 2012; Gehrke, Wu et al. 
2015). First of all, ribosomes are found to locate on the surface of mitochondria 
(Kellems and Butow 1972; Keyhani 1973). Secondly, about 500 mRNAs were 
estimated to reside close to mitochondria. Furthermore, the authors show that the 
localised mRNAs are likely to be ancient with bacterial origins (Marc, Margeot et al. 
2002; Saint-Georges, Garcia et al. 2008). The association of mRNA in the vicinity of 
mitochondria requires the presence of protein import machinery, the cis-acting 
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sequences and the RBP (Eliyahu, Pnueli et al. 2010; Gadir, Haim-Vilmovsky et al. 
2011). The best-studied mRNA binding protein involved in localisation of NEMP 
mRNA is the yeast PUF3p.  
 
1.3.3 PUF3p  
 
The yeast PUF3p is one of the six PUFs (Pumilio and FBF) with known RNA binding 
domains. Members of this family are well conserved from yeast to human and can 
recognise the specific sequence at the 3´-UTR in order to regulate mRNA localisation, 
translation and stability (Wickens, Bernstein et al. 2002). Yeasts contain five PUFs, 
Drosophila, one, mammals, two. The RNA binding motif of RBP and the RNA 
signature for binding of the targets are also well conserved (Wickens, Bernstein et al. 
2002). The RNA binding domain of PUF proteins are PUM-HD-type which forms an 
arc-like shape that can interact with both RNA and protein (Zamore, Williamson et al. 
1997; Zhang, Gallegos et al. 1997). Members of this protein family display different 
functions, they can either suppress or activate translation or involved in targeting 
mRNA to subcellular localisation/organelle (Murata and Wharton 1995; Sonoda and 
Wharton 1999). In Drosophila, PUMILIO can repress the translation of hunchback 
during early embryogenesis. Yeast Puf6p can regulate both localisation and translation 
of ASH1 for mating type switching while Puf5p can affect the localisation of PEX14 to 
peroxisomes (Wreden, Verrotti et al. 1997; Zipor, Haim-Vilmovsky et al. 2009). 
Puf3p binds preferentially to approximately 162 mRNAs of NEMPs in yeast to facilitate 
localisation and co-translational import. The protein products of these mRNAs are 
involved in mitochondrial protein synthesis, structural components of the ribosome, 
tRNA ligases, OXPHOS and translational regulators (Huh, Falvo et al. 2003; Gerber, 
Herschlag et al. 2004). Puf3p is also found to be a component of P-body under stress 
(Lee, Dudley et al. 2009; Eliyahu, Pnueli et al. 2010). In the absence of Puf3p, the target 
mRNAs mislocate (Olivas and Parker 2000; Saint-Georges, Garcia et al. 2008; Eliyahu, 
Pnueli et al. 2010). Puf3p associate with mitochondria via binding to Mdm12, the 
component of ER-mitochondria encounter structure (Garcia-Rodriguez, Gay et al. 2007).  
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One would expect that Puf3p could be important for mitochondrial biogenesis regarding 
its molecular function, however in reality, it is more complicated. Mitochondrial 
biogenesis and Puf3p reduction occur at the same time, and both overexpression and 
deletion lead to impairment in respiratory growth (Gerber, Herschlag et al. 2004; 
Garcia-Rodriguez, Gay et al. 2007; Saint-Georges, Garcia et al. 2008; Eliyahu, Pnueli et 
al. 2010). Puf3p activity is dependent on the carbon source without alteration in 
transcript or protein level. (Gerber, Herschlag et al. 2004; Foat, Houshmandi et al. 
2005). Furthermore, Puf3p is essential for the growth of TOM20 mutant yeast in 
glycerol. In the absence of TOM20, puf3 mRNA increases and so is its protein level, 
however Puf3p associates less with the mitochondria (Eliyahu, Pnueli et al. 2010). 
Moreover mitochondria in Δpuf3 are fragmented and aggregated with impaired 
anterograde movement (Garcia-Rodriguez, Gay et al. 2007). Based on these 
observations, it is suggested that Puf3p exists as two pools: mitochondrial and non-
mitochondrial. Puf3p on mitochondria localises and tethers the mRNAs to mitochondria. 
Non-mitochondrial Puf3p locates in the cytoplasm and may inhibit translation when 
mitochondrial biogenesis is not required (Garcia-Rodriguez, Gay et al. 2007; Quenault, 
Lithgow et al. 2011).  
It is worth remembering that Puf1p also localises to mitochondria and facilitates the 
association of mitochondria to Arp2/3 complex of actin in yeast (Moreau, Madania et al. 
1996).There are two Pumilio homolog (PUM1 and PUM2) in human (Spassov and 
Jurecic 2002; Galgano, Forrer et al. 2008). PUM2 knockout mice displays smaller testis 
but without obvious effect on fertility (Xu, Chang et al. 2007). The mRNA targets of 
PUM1 shares little similarity to Puf3p or Pumilio and is not enriched for NEMP (Gerber, 
Herschlag et al. 2004; Gerber, Luschnig et al. 2006; Morris, Mukherjee et al. 2008) 
despite the conservation of the protein binding domain and RNA motif. There is no 
protein with similar role to Puf3p that has been identified so far in mammalian system. 
Furthermore, it is unclear if mRNA localisation to mitochondria occurs at all in the 
mammalian system.  
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1.4 CLUH  
 
1.4.1 Clu mutant leads to mitochondrial clustering and abnormal mitochondrial 
morphology 
 
Clu stands for clustered mitochondria and is well conserved from amoeba to human (see 
the gene and protein annotations in Table 3). For the sake of simplicity, all homologs 
mentioned below will be referred as Clu when general function is introduced. Its name 
originated from the phenotype of mitochondrial clustering after clu is deleted. CluA was 
first identified in 1992 as an unconventional myosin in Dictyostelium because of its 
cross-reactivity with the antiserum specific for myosin-IC (Zhu and Clarke 1992). 
However it neither possesses any myosin like activity nor shares significant homology 
to myosin (Zhu, Hulen et al. 1997).  
 
Table 3: Annotation of clu genes and proteins in different organisms. 



















Tetratricopeptide repeat (TPR) 






















In Dictyostelium, when cluA is deleted, mitochondria cluster at the cell center while 
peroxisomes and ER remain morphologically unchaged (Zhu and Clarke 1992; Fields, 
Arana et al. 2002). Disruption of microtubules or actin filaments, does not affect the 
distribution of existing mitochondria (i.e. mitochondria that were already transported to 
the positions) (Fields, Arana et al. 2002). Mitochondria within the cluster are free to 
undergo deformation and rearrangement, however, individual mitochondrion appears to 
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have constrained movement. Half of the CluA mutants are multinucleated, indicating a 
failure in cytokinesis.  
Yeast mitochondria in clu1Δ cells were condensed and accumulated on one side of the 
cell. However, the inheritance of functional mitochondria to daughter was not affected. 
No multinucleated cells were observed in yeast mutants. Interestingly, yeast Clu1p 
(sharing only 50 % similarity in primary structure to CluA) can correct the cytokinetic 
defect in Dictyostelium cluA- cells to wildtype level. However it can only partially 
rescue the mitochondrial clustering phenotype in cluA- cells: Clu1p complemented 
mitochondria were dispersed in the cytoplasm but in the form of small aggregates 
(Fields, Conrad et al. 1998). The Arabidopsis homolog friendly mitochondria (FMT, 
also known as noxy 38 or friendly) also gave rise to clustered mitochondria (Logan, 
Scott et al. 2003; Vellosillo, Aguilera et al. 2013; El Zawily, Schwarzlander et al. 2014). 
However only a portion of total mitochondria were clustered, others resemble 
mitochondria in the wildtype cells. Consistent with the observation in Dictyostelium, 
other organelles in Arabidopsis mutant are not affected morphologically (El Zawily, 
Schwarzlander et al. 2014). Importantly, two fmt mutations were studied and both led to 
aggregated (clustered) mitochondria. Fmt mutant identified by Logan and colleague 
contains G-to-A mutation of the first base of the second intron and this result in almost 
complete absence of the respective transcript. In contrast, Vellosio and colleague´s 
noxy38 mutant contains G-to-A transition in the last nucleotide of intron 22. This 
transcript is translated into a truncated protein (1053 amino acids) without the TPR 
domains (see more information of this domain later). 
In Drosophila clueless mutants, mitochondria clustered in the anterior region of 
germline stem cells, mitotic germline stem cells, old germ cells, stage 5 nurse cells, 
somatic follicle cells and neuroblast cells (Cox and Spradling 2009; Sen, Damm et al. 
2013). Mitochondrial clusters were present in microtubule plus end (Cox and Spradling 
2009). Moreover, the electron microscope (EM) data showed swollen mitochondria 
with loss of cristae in the 3-days old flight muscles and ovaries. Sperm from sterile male 
mutants was immobile and the spermatide mitochondria derivative was irregular and 
swollen. Most interestingly, the fly mutant with double heterozygous park (gene 
associates with Parkinson´s) and clu leads to clustered mitochondria suggesting that 
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these two proteins genetically interact. The clustering phenotype of mitochondria was 
also observed in mouse, monkey and human cells (Gao, Schatton et al. 2014).  
Analyses were conducted to understand mitochondrial clusters. The EM images of 
mitochondria from cluA- cells displayed interconnection between neighboring 
mitochondria. This observation suggests a failure of mitochondrial fission at a very late 
stage (Fields, Arana et al. 2002). However, interconnected mitochondria were not 
observed in the other organisms. The clustered mitochondria in Arabidopsis did not 
have interconnected OM between mitochondria (Logan, Scott et al. 2003; El Zawily, 
Schwarzlander et al. 2014). However, electron dense regions were observed between 
individual mitochondrion within a cluster of the mutant.  
The cytoskeleton in all Clu mutants appeared to be intact and functional (Zhu and 
Clarke 1992; Fields, Arana et al. 2002; Cox and Spradling 2009). Moreover 
mitochondrial transport was unaffected (Cox and Spradling 2009; El Zawily, 
Schwarzlander et al. 2014). Deletion of Clu did not affect the transport and 
accumulation of mitochondria to Balbiani bodies (Balbiani body is a collection of 
organelles, mRNA and inclusions present in the early oocyte of all animals, it is 
normally close to the nucleus.). In friendly mutant, small mitochondrial aggregates as 
well as individual mitochondrion could be transported on actin. Altogether, these 
evidences indicate that mitochondrial clustering phenotype is independent of 
cytoskeletal alteration and defects in mitochondrial transport. It is postulated that the 
clustering phenotype might be caused by prolonged association between mitochondria 
(El Zawily, Schwarzlander et al. 2014). 
 
1.4.2 Clu mutants of multicellular organism display growth defects 
 
Clu function is not essential for single cellular organisms. Dictyostelium cluA- mutant 
displayed a moderate reduction for growth that could be caused by unequal distribution 
of mitochondria after cell division (Zhu, Hulen et al. 1997). Yeast clu1Δ mutants 
showed no defect in growth in non-fermentable media (glycerol, lactate and ethanol), 
glucose media, heat and osmotic stress (Fields, Conrad et al. 1998). No signs of failure 
in cell wall synthesis or mitochondrial membrane potential were observed in yeast. It 
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was not even considered to be an essential gene in yeast, since TIF31 mutant could still 
grow at temperatures higher or lower than 30oC (Vornlocher, Hanachi et al. 1999).  
Arabidopsis Friendly mutant leaves were smaller, shorter and more rounded than the 
wildtype (El Zawily, Schwarzlander et al. 2014). The length and width of root were 
significantly reduced and this might due to increased cell death. Along with this, the 
mutant root displayed increased number and size of acid vacuoles (El Zawily, 
Schwarzlander et al. 2014). Interestingly, the noxy38 mutant was more susceptible to 
pathogen invasions (Vellosillo, Aguilera et al. 2013).  
Despite the clustering phenotype during development, the fly clueless mutants strived to 
adulthood. However, there was a prolonged larval development. At the end, only 40 % 
of the pupae can manage to eclose (Sen, Damm et al. 2013). These flies then developed 
phenotypes similar to park and pink1 mutants: short lifespan, small size, un-
coordination, sterility, flight muscle defects (wings up and down) and problems with 
utilising larval fat body in the new adults (Cox and Spradling 2009) (Goh, Zhou et al. 
2013). Clu was highly expressed in neuroblasts but functionally dispensable (Goh, Zhou 
et al. 2013; Sen, Damm et al. 2013). In Clu mutant neuroblasts, mitochondria were not 
evenly segregated into the daughter cells. However, this did not have any impact on cell 
development or mitochondrial numbers. 
Little is known regarding the function of clu1 in C. elegans, however genomic RNAi 
studies revealed that clu-1 mutant is embryonic-lethal (6 %, 24 hours recovery after 
soaking the worms with RNAi) (Maeda, Kohara et al. 2001). Interestingly, 
mitochondria are not clustered in C. elegans (Logan, Scott et al. 2003). However, it is 
not clear if the above RNAi data on C. elegans can be correlated.   
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1.4.3. Primary structure and the molecular function of Clu 
 
The structure and molecular functions of Clu proteins are unknown, however 
provisional bioinformatics studies show that all Clu homologs share similar domains 
arrangement: CLU_N domain also known as TIF31-like, GSKIP domain, CLU domain, 
eIF_ p135 (or Clu_central) domain and finally the TRP domain (Figure 7). 
The nomenclature of TIF31 and eIF_p135 domain was based on the finding of 
Vornlocher et al. that TIF31 co-purified with eukaryotic translation initiation factor 
eIF3 (Vornlocher, Hanachi et al. 1999). However, deletion of TIF31 affected neither the 
function of eIF3 nor the global cytosolic translation. Moreover, TIF31 is neither always 
associated with eIF3 complex nor identified in eIF3 complex in human or plant 
(Browning, Gallie et al.). Consequently, Clu is not considered as part of the core eIF-3 
complex despite its interaction with p33 (or TIF35, eIF3G, an essential eIF3 subunits) in 
yeast. There is no evidence so far that Clu plays any roles in translation.  
The TPR motif contains degenerate sequences and proteins with these repeats act as 
scaffolds for the assembly of multicomplexes or protein-protein interactions. As 
mentioned before, truncated FMT protein without the TPR domains can lead to 
mitochondrial clustering phenotype. Moreover, FRIENDLY protein is subjected to post-
translational modification, it contains two acetylation sites Lys-1022 and Lys-1029 
which is located in between eIF_p135 and TPR domains (Finkemeier, Laxa et al. 2011; 
El Zawily, Schwarzlander et al. 2014). The acetylation status of FRIENDLY might be 
involved in mitochondrial clustering and other functions.   
I n t r o d u c t i o n  | 33 
 
Figure 7: Illustration of the predicted protein domain of CLUH. CLU_N domain is also 
known as TIF31-like, eIF_p135 domain is also known as CLU-central. Protein domain 
information obtained from NCBI Conserved domains and InterPro from EMBL-EBI (for 
GSKIP domain). Protein domains are annotated with DOG (Ren, Wen et al. 2009). 
 
It is also interesting to note that the mRNA level of cluA is elevated from the vegetative 
stage to the developing stage of the cell (Zhu, Hulen et al. 1997).  
Clu locates in the cytoplasm as discrete puncta / granule (Fields, Conrad et al. 1998; 
Fields, Arana et al. 2002; Cox and Spradling 2009; Gao, Schatton et al. 2014). Some 
Clueless particles were observed outside of mitochondria, while some other associated 
with microtubules. However it is not clear if Clueless particles, mitochondria and 
microtubules colocalise (Cox and Spradling 2009). The ovary microtubule network in 
clueless mutants remained undisrupted. Deletion of Clu in flies and mammalian cells 
led to reductions of a subset of mitochondrial proteins (Cox and Spradling 2009; Gao, 
Schatton et al. 2014).  
Transcriptome studies of Clu mutants indicated mitochondrial dysfunction. Gene 
expression study of the mild clueless mutant (with low expression level of Clu) showed 
downregulation of genes involved in reactive oxygen species protecting agents, DNA 
repair, apoptosis regulator and fatty acid production regulator. Some candidate 
metabolic genes involved in amino acid/fatty acid transporter, putative choline 
transporter and putative aminoadipate-semialdehyde were upregulated (Cox and 
Spradling 2009). Transcriptome analysis in Arabidopsis indicates alteration in genes 
I n t r o d u c t i o n  | 34 
 
involved in protein synthesis, degradation, photosynthesis, photosynthetic light reaction, 
abiotic stress, redox and TCA cycle (El Zawily, Schwarzlander et al. 2014).  
Biochemical analysis of the mutants in different organisms also suggests defects in 
mitochondria. In Arabidopsis, mutation induced the upregulation of the alternative 
oxidase pathway without affecting the average oxygen uptake (Vellosillo, Aguilera et al. 
2013; El Zawily, Schwarzlander et al. 2014). AOX directs reduction of oxygen with the 
electrons donated from ubiquinol. Therefore, it reduced the total electron flow to 
complex III and the eventual production of ATP. Similarly, clueless adult mutants 
displayed severely reduced level of ATP as well as aconitase activity. However both 
phenotypes were absent in the mutant larvae.  
Investigation of the neuroblasts of Clueless mutant showed that Clu was important for 
the asymmetric cell division of neuroblasts. Neuroblast asymmetric cell division 
generates one big daughter neuroblast cell and another small ganglion mother cell. 
These two cells inherit different materials including cell fate determinants Numb and 
Miranda. Numb and Miranda are positioned to the basal cortex of neuroblasts before 
mitosis. After cell division, they are inherited by ganglion mother cell. Positioning of 
the cell fate determinants is achieved by phosphorylation conducted by the Par complex. 
Par complex is composed of atypical protein kinase C (aPKC), Defective 6 (Par6) and 
Bazooka. In interphase, Par6 and aPKC are associated with lethal giant larvae (Lgl). It 
is proposed that aPKC/Baz/Par6 (active) complex is in equilibrium with aPKC/Lgl/Par 
6 (inactive) complex in the apical cortex to direct the phosphorylation of cell fate 
determinents Miranda and Numb. Phosphorylation of these proteins results in exclusion 
of their apical position. Interestingly, a small portion of neuroblast mutant cells 
displayed mislocalised Miranda during metaphase. Clu was mainly if not exclusively 
present in the neuroblasts throughout asymmetric cell division (Goh, Zhou et al. 2013; 
Sen, Damm et al. 2013). In addition, Clu coimmunoprecipitated with aPKC and Baz but 
not Lgl. Lgl mutant also led to mislocalisation of Miranda and Numb to a large extent 
and mislocalisation could be rescued by depleting clu or park. The author concluded 
that the function of park and clu is likely to be independent from mitochondrial function 
during neurogenesis (Goh, Zhou et al. 2013). However according to Sen and colleagues, 
the number of neuroblats in clu mutant were comparable to the wildtype and neurons 
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can differentiate properly. Therefore it is still unclear why neuroblasts require high 
expression level of Clu.  
In spite of mitochondrial clustering phenotype, Clu is a cytosolic protein and might be 
located in close proximity to mitochondria (Cox and Spradling 2009). The relationship 
between clu and mitochondria remains to be elucidated.   
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2 Aim of the Thesis 
 
Mitochondria are indispensible organelles to support the normal function of cells in all 
eukaryotic systems, including mammals. The status of mitochondria in response to 
metabolic alteration and signaling is vital for cell survival. It is well established that 
mitochondrial biogenesis requires concerted coordination between the nuclear and 
mitochondrial genomes. This process demands the participation of armies of factors: 
transcriptional regulators, transcriptional factors, mRNA export of nucleus, mRNA 
transport and localisation, translation, post-translational modification, protein folding, 
and protein import to mitochondria. 
Accumulated evidences in different organisms indicate the important relationship 
between Clu and mitochondria. Clu is a well-conserved cytosolic protein with a 
similarly conserved peculiar mitochondrial clustering phenotype, yet its function 
remains to be elucidated. Despite being a cytosolic protein, Clu is proposed to be 
involved in regulating mitochondrial position in response to physiological changes. A 
small portion of Clu is observed in close proximity to mitochondria. It can affect the 
protein levels of OXPHOS while genetically interacting with Park in Drosophila. In 
yeast, Clu copurifies with eIF3, however it is not an essential components of the 
cytosolic translation machinery.  
The aim of this project is to investigate the molecular function of CLUH in mammalian 
system in order to address the following questions: (1) what is the molecular function of 
CLUH? (2) What is the relationship between CLUH and mitochondria? (3) How is 
CLUH regulated transcriptionally and in respect to cellular alterations?
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All chemicals used in this study were purchased from Merck, Sigma-Aldrich, Serva or 
Roth unless stated otherwise.  
 
3.1 Cell biology 
 
3.1.2 Cell culture  
 
Mouse embryonic fibroblasts (MEFs) and HeLa cells were cultured in DMEM (Life 
Techologies, 11960085), supplemented with 10 % FCIII (HyClone, FetalCloneIII, 
SH30109.03, Life Techologies), 2 % penicillin-streptomycin (Life Technologies, 
151401232), and 2 mM L-glutamine (Life Technologies, 25030024). NSC34 cells 
(Cashman, Durham et al. 1992) were cultured in DMEM, supplemented with 10 % defined 
FBS (Life Techologies, SH30070.03), 2 % penicillin-streptomycin, and 2 mM L-glutamine. 
HEK 293T cells were maintained in media containing DMEM, 7.5 % tetracycline-free fetal 
bovine serum (Biochrom AG, S0115), 1 mM sodium pyruvate (Life Technologies, 1136-
070), 1x non-essential amino acids (Life Technologies, 1140-035), 2 mM L-glutamine and 
1.5 mg/ml of hygromycin (Invivogen, ant-hm-5) and 150 µg/ml of blasticidin (Invivogen, 
ant-bl-5b). 1 g/ml of tetracycline (dissolved in ethanol) was used to induce protein 
expression.  
PGC-1α MEFs were kindly provided from Dr. Tina Wenz. The embryos were collected at 
E12.5, and immortalized using the classic 3T3 protocol. PGC-1α knockout mice were 
obtained by breeding PGC-1α floxed (http://jaxmice.jax.org/strain/009666.html) with a full 
body Cre-deletor mouse line. 
Cluh knockout MEFs were prepared by Dr. Henriette Hansen. 
 
3.1.3 Long-term galactose experiment 
 
The scheme of the galactose experiment is provided below (Figure 8). In general, HeLa 
cells were cultured in galactose media containing DMEM (glucose free, Life Technologies, 
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11966-025), 10 % dialysed serum (Life Technologies, 26400-036) 1 mM sodium pyruvate; 
6 mM galactose and 2 % penicillin-streptomycin). Galactose media were changed every 24 
hours.  
 
Figure 8: Experimental scheme of long-term galactose treatment. 
 
3.1.4 Short-term galactose and acetoacetate treatment  
 
The treatment was performed by Dr. David Pla-Martin. Briefly, 400,000 of MEF cells were 
plated on P60 plates and incubated in complete DMEM for overnight. The media was 
replaced with media containing galactose or acetoacetate (glucose free DMEM, 10% 
dialysed FBS, 100 mM acetoacetate (Sigma-Aldrich, 164100-50G) and 2 % penicillin-
streptomycin). 
 
3.1.5 Bezafibrate treatment  
 
The treatment was conducted in MEFs as illustrated below (Figure 9). Bezafibrate solution 
(B7273, sigma) was prepared by dissolving 0.199 g of bezafibrate in 2 ml of DMSO 
(100%) for a final concentration of 275 mM. MEFs were treated with a final concentration 
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of 550 µM (10µl for 5 ml of complete media) and 0.2 % DMSO was added to the control 
MEFs. 
 
Figure 9: Experimental scheme of bezafibrate treatment. 
 
3.1.6 RNA interference 
 
NSC34 were grown to 70-80 % confluence. Either one or all three siRNAs (Table 4) 
against murine Cluh (Life Technologies) were transfected in a 1:1:1 ratio (final 
concentration was 100 nM) using Lipofectamine® 2000 (Life Technologies, 11668). Cells 
were collected for experiment 72 hours after the transfection.  
 





3.1.7 Immunofluorescence and imaging  
 
Cells were washed twice with PBS and fixed with 4 % paraformaldehyde pH7.4 in PBS for 
30 min at RT or with ice-cold methanol for 20 min at -20°C. Cells were then permeabilised 
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with 0.2 % Triton X-100 in PBS for 10 min at RT. Cells were blocked in 10 % pig serum 
in PBS for 10 min and subjected to primary antibodies diluted in PBS including 1 % pig 
serum for 2 h at RT (See Table 5 for the information of primary antibodies). Afterwards, 
cells were washed in PBS and incubated in secondary antibodies diluted in PBS and 1 % 
pig serum for 1 h at RT (See Table 6 for the information of secondary antibodies). Cells 
were then washed twice with PBS for 5 min, followed by DAPI staining (1:2,000 in PBS, 
Sigma-Aldrich, D9542-5MG) for 5 min and mounted with Fluorsave (Calbiochem, 
345789). Images were taken with an epifluorescence microscope Imager.M2m (Zeiss) 
using an ApoTome module with 63x 1.4 NA oil immersion objective lens. The software 
AxioVision Version 4.8 2.0 was used for Image acquisition. Images represent a single-
plane with a thickness of 0.250 μm. 
 
Table 5: Primary antibodies used for immunofluorescence 
Primary Antibody Dilution 
CLUH 06, Novus Biologicals, NB100-93306 1:500 
COX1, Life Tecnlogies, A6403 1:1000 
FLAG Sigma-Aldrich, F3165 1:5000 
TOM20, Santa Cruz, sc-11415 1:500 
   
 
Table 6: Secondary antibodies used for immunofluorescence 
Secondary Antibody Dilution 
AlexaFluor 594, Donkey anti-rabbit 
Life Technologies, A-21207 
1:500 
AlexaFluor 488, Chicken anti-mouse 
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3.2 Molecular biology 
 
3.2.1 Polymerase chain reaction (PCR) and agarose gel electrophoresis 
 
Full length human CLUH was cloned from pcDNA3-hCluFL generated by Dr. Paola 
Martinelli. CLUH with p3x FLAG (Sigma-Aldrich, E7980) at its C-terminus was created 
by inserting full length human CLUH into the multiple cloning site of p3xFLAG-CMV-14 
via HindIII and EcoRI. Addition of restriction sites HindIII and EcoRI to CLUH and the 
removal of stop codon were conducted by PCR (forward primer contains HindIII 
restriction site: 5´- GCAAAGCTTATGGTTATCAAGACG-3´ reverse primer contains 
EcoRI site: 5´- CTCCGAGCGTGCAGGGACGGAATTCCG-3´). PCR was performed 
with Pfu DNA polymerase (Life Technlogies EP0571), 1 µM final concentration of 
primers, 200 µM final concentration of dNTPs and 1 x Pfu buffer. PCR thermocycler was 
set as below:  
 
Temperature Time  
95oC 3 min  
95oC 30 s  
       35 Cycles 
55oC 30 s 
72oC 9 min 
72oC 15 min 
16oC Hold  
 
 
PCR products were then resolved in terms of agarose gel electropheresis. The gels were 
prepared in TAE buffer (40 mM Tris-Cl pH8, 40 mM aceticacid and 1 mM EDTA). 
Ethidium bromide was used to the gel for DNA visulisation. The samples were mixed with 
loading dye (0.1 % SDS, 15 % glycerol, 10 mM Tris-Cl pH8, xylene cyanol FF, 
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3.2.2 Gel extraction, DNA extraction, DNA digestion and ligation 
 
After excising the PCR product from the agarose gel, DNA was extracted with Gel 
Extraction Kit (Qiagen, 28706) following the manufacturer's manual. PCR products and 
p3xFLAG-CMV-14 vector were restricted by HindIII (NEB, R0104) and EcoRI (NEB, 
R0101) at 37oC for 2 hours. The restricted vectors were separated and purified by agarose 
gel electrophoresis and gel extraction, respectively, whereas the PCR products were 
precipitated with ethanol. DNA precipitation was achieved by mixing the PCR product 
with 1 µl of glycogen, 300 mM final concentration of sodium acetate and equal volume (to 
PCR product) of absolute ethanol. The mixture was incubated at -20oC for 10 min and 
centrifuged at 20,000 g for 30 min at 4oC. After removing the supernatant, DNA pellet was 
air dried and dissolved in 50 µl of H2O. The ligation reaction between restricted PCR 
products and vectors were perfomed with the T4 DNA ligase (NEB, M0202) according to 
the manual at 16oC for overnight. 
 
3.2.3 Bacterial transformation and colony selection 
 
Competent E. coli (strain DH5α) were transformed by heat shock with the ligated 
plasmids. Bacteria and DNA were incubated on ice for 30 min and heat shocked for 2 min 
at 42°C followed by incubation on ice for 2 min. Then 900 μl of SOC medium (20 g 
Tryptone (NZCym), 0.5 % (wt/v) of yeast extract, 8.6 mM NaCl, 25 mM KCl, 10 mM 
MgCl2, 2 mM glucose) was added to the bacterial mixture and incubated for 30 min at 
37°C. After centrifugation of bacteria at 4,000 g for 1 min, the transformed bacterial pellet 
was plated on a LB-agar plate containing 100 μg/ml of ampicillin and incubated for 
overnight at 37°C. 
 
Colonies were picked on the next day and inoculated into LB-medium containing 100 
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3.2.4 Generation of CLUH-FLAG and CLUH deletion HEK 293T cell lines 
 
Recombination sites attB1 and attB2 were inserted to all CLUH constructs by PCR (see 
Table 7 and 8 for primer information) with Pfu DNA polymerase.  
 











Table 8 Combinations of primers used for different constructs 
Construct Forward primer  Reverse primer  
Δ1021-1347 CluC_st_F CluC_st_R 
Δ801-1347 CluC_st_F CluC_st_R 
Δ1-352 ΔGSKIP _st_F CluC_st_R 
Δ1-615 ΔGSKIP_Δclu_st_F CluC_st_R 
 
After agarose gel electrophoresis and gel extraction, the PCR products were then inserted 
into Gateway®pDONR™ 221(Life Technologies, 12536-017) using Gateway® BP Clonase® 
(Life Technologies, 11789-021) according to instruction. The BP recombination reaction 
was performed for overnight at RT. On the next day, the recombined vector was 
transformed into One Shot® OmniMAX™ 2 T1Rcells (Life Technologies, C8540-03) with 
heat shock. The transformed bacteria were then allowed to grow on LB-plate containing 50 
μg/ml kanamycin. After picking the positive clones and sequencing, the correct constructs 
were subjected to LR recombination reaction to facilitate the transfer of CLUH constructs 
to Gateway®pT-REx™-DEST30 vector (Life Technologies, 12301-016) using Gateway® 
LR Clonase® (Life Technologies, 11791-019) for overnight at RT according to instruction. 
The reaction mix was then transformed into One Shot® STBL3 cells by heat shock (Life 
Technologies, C7373-03). After overnight growth on LB plate containing 50 μg/ml of 
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ampicillin, positive clones were picked and inoculated for culturing. The final constructs 
were obtained by Miniprep Kit. 
HEK 293T cells were cultured without any antibiotics and passaged for five times before 
transfection. 0.5 µg of DNA constructs and 2.5 µg of pOG44 Flp-Recombinase expression 
vector (Life Technologies, V6005-20) were transfected with Lipofetamine® 2000 per 6 
well plate. Selection started 24 hours after transfection by replacing culturing media to that 
containing hygromycin and blasticidin. Clones were picked by pipetting. 
 
3.2.5 Crosslinking immunoprecipitation (CLIP) and RNA immunoprecipitation  
 
Cells were splitted one night before UV crosslinking and harvested at about 70-80 % of 
confluence. HeLa and HEK 293T cells were rinsed with DPBS (Life Technologies, 
14190169) and crosslinked with 300 mJ and 400 mJ, respectively (UVP UV crosslinker, 
CX2000). Afterwards, cells were collected and centrifuged at 21,000 g for 15 s. Cell 
pellets were then either stored at -80oC or used immediately for CLIP experiment. Cell 
pellet was lysed in cold lysis buffer (50 mM Tris-Cl pH 7.4, 100 mM NaCl, 1 mM MgCl2, 
0.1 mM CaCl2, 1 % IGEPAL® CA-630, 0.1 % SDS and 0.5 % sodium deoxycholate) 
supplemented with different concentrations of RNase I (Life Technologies, AM2294) (50 
U/500 µl lysate or 1 U/500 µl lysate) and 4 U TurboTM DNase (Life Technologies, 
AM2238) per 500 µl of lysate. DNase/RNase treatment was conducted at 37oC for 5 min 
with shaking (1100 rpm) and then cooled on ice for 2 min. Cell lysate was cleared by 
centrifugation at 21,000 g for 25 min. 450 µl of cleared lysate was then incubated with 0.5 
µg of anti-CLUH 06, 0.5 µg anti-Afg3l1(Koppen, Metodiev et al. 2007), no antibody, or 3 
µg of anti-FLAG for 1 h at 4oC with head-to-toe rotation. The complex was 
immunoprecipitated by adding 20 µl protein G Dynabeads (Life Technologies, 10003D) 
for 1 h at 4oC. The beads were then washed extensively with 1 ml lysis buffer (3 times and 
each time with 5 min head-to-toe rotation) followed by 1 ml of high salt buffer (50 mM 
Tris-Cl pH 7.4, 1 M NaCl, 1 % IGEPAL® CA-630, 0.1 % SDS, 0.5 % sodium 
deoxycholate and 1 mM EDTA) (2 times and each time with 5 min head-to-toe rotation). 
Immunoprecipitated complexes were then washed with 1 ml T4 PNK buffer (20 mM Tris-
HCl pH 7.4, 10 mM MgCl2 and 0.2 % Tween-20). RNA end-labeling was carried out by 
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incubating the beads with 1 µl PNK buffer, 2 µl T4 PNK (20 unit, NEB), 1 µl of ATP γ-P32 
(10 mCi/ml, Perkin-Elmer) and 33 µl of H2O at 37
oC for 5 min with agitation. The beads 
were then washed with 1 ml PNK buffer plus 20 mM EGTA (for 3 times and each time for 
5 min), and then with 1 ml high salt buffer (for 2 times and each time for 5 min). The RNP 
complex was then released by incubating the beads with 1x BoltTM LDS sample buffer 
(Life Technologies, B0007) and 1x of BoltTM reducing agent (Life Technologies, B0004) 
at 70oC for 10 min with agitation. The samples were resolved onto 4-12 % Bolt® Bis-Tris 
Plus (Life Technologies, NW04120BOX), the gel was dried and exposed to obtain 
autoradiograph. For RNA immunoprecipitation, the procedure was the same, except that no 
RNase I was added to the lysis buffer and without RNA end labelling.  
 
3.2.6 RNA extraction  
 
The immunoprecipitated RNA was extracted by incubating the beads with 10 % SDS and 
100 µg of proteinase K (Promega, V3021) at 37oC for 30 min, followed by 
phenol/chloroform/isoamyl and acid/chloroform extraction (ToTALLY RNATM kit, Life 
Technologies AM1910,). Precipitation of RNA was achieved by addition of isopropanol 
and GlycoBlue (Life Technologies, AM9515) and incubation at -20°C for overnight. After 
centrifugation at 12,000 g for 15 min, the RNA pellet was washed with 70 % ethanol and 
dried in the air. 
RNA extractions of HeLa cells after galactose treatment and MEF cells were performed 
with TRIzol® and RNA was extracted according to the manufacturer´s manual (Life 
Technologies, 15596-026,). 
 
3.2.7 Reverse transcription and quantitative real-time PCR 
 
The immunoprecipitated RNA from CLIP experiments or 5 μg of total RNA from total 
RNA extracts were reverse transcribed with SuperScript® First-Strand Synthesis System 
(Life Technologies, 11904-018) with oligodT as primers according to manufacturer´s 
manual.  
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Real-time PCR was performed with SYBR® green Master Mix (Life Technologies, 
4309155,) and 500 nM of each primer (Table 9). cDNA from whole cell extracts were 
diluted 1:10 and 1 µl was used per 12.5 µl of reaction per well. cDNA synthesized from 
RNA immunoprecipation was used without any dilution. Each reaction was performed in 
triplicate, and at least three biological repeats were conducted. The fold enrichment was 
calculated with formula: 2(-DDCt). 
Table 9: Primers used for Q-PCR 












































Human CLUH hCLUH_Q_F ACCGGCAAGTCAGCATCAC 
hCLUH_Q_R1 AAGGTCGGGCTGATCTGGTT 
Mouse Cluh forward GGTAGCGGGCACGGTACA 
reverse GCATTGAGCACCCCAACAC 
Mouse Afg3l2 forward AGGACGACTTGAGGAAGGTTACC 
reverse GCCCCACTTTCTCGTTCATG 
Mouse Atp5a1 forward TGGGCCGTGTGGTTGAC 
reverse CGTCTGCGGGTCTTGGAA 
Mouse Ogdh forward TGGTGTCGGCGCTTCACT 
reverse TGTCCTGAAGCCTTCCACAAG 
Mouse Sdha forward GGCAGGCTCATCGGTGTT 
reverse CATATCGCAGAGATCTTCCATAC 
Mouse Tom20 forward AGCTGGGCTTTCCAAGTTACC 
reverse ACCAAGCTGTATCTCTTCAAGGA 
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3.2.8 RNA sequencing and analysis 
 
For RIP, the procedure was the same as described above, except that no RNase I was added 
to the lysis buffer. The following steps were conducted by Cologne Center for Genomics 
(CCG). Libraries were prepared using the Illumina® TruSeq® RNA Sample Preparation 
Kit v2. Starting material was 1µg total RNA from the input samples, and complete material 
of the RIP experiments (240-550ng RIP RNA). After poly-A selection (using poly-T oligo-
attached magnetic beads), mRNA was purified and fragmented using divalent cations 
under elevated temperature. The RNA fragments underwent reverse transcription using 
random primers. This was followed by second strand cDNA synthesis with DNA 
Polymerase I and RNase H. After end repair and A-tailing indexing adapters were ligated. 
The products were then purified and amplified (15 PCR cycles) to create the final cDNA 
libraries. After validation (Agilent 2200 TapeStation) and quantification (Life 
Technologies Qubit System) the pool was quantified by using the Peqlab KAPA Library 
Quantification Kit and the Applied Biosystems 7900HT Sequence Detection System. The 
pool was loaded on an Illumina HiSeq sequencer and TruSeq PE Cluster FlowCell and 
sequenced by using one 2x100bp lane on an Illumina HiSeq 2000 Sequencer. 
The following steps were performed by Dr. Peter Frommolt, Bioinformatics Facility, 
CECAD. Data were analyzed using a high-throughput Next-Generation Sequencing 
analysis pipeline: Basic read quality check was carried out using FastQC and read statistics 
were obtained with SAMtools. Reads were mapped to the human reference assembly, 
version GRCh37, using TopHat2 (Kim, Pertea et al. 2013), and gene quantification was 
carried out using a combination of Cufflinks (Trapnell, Williams et al. 2010) and the 
DEseq2 package (Anders and Huber 2010) with genomic annotation from the Ensembl 
database, version 77. The results were uploaded into an in-house MySQL database and 
merged with annotations obtained with BiomaRt from Ensembl, version 77. The gene lists 
were filtered according to FC and P-value in comparison of the library-size normalized 
read counts between samples and controls. The sample and control means as well as FC 
and P- were calculated with the DESeq2 package from the Bioconductor project. Wald's 
test was used for significance testing. In contrast, gene expression for the individual 
samples was calculated by the Cufflinks package and returned as FPKM (Fragments Per 
Kilobase of transcript per Million mapped reads) values, which means that they have been 
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normalized also by the molecule size.Analysis of enriched pathways and gene annotations 
were performed using Ingenuity Pathway Analysis. To exclude false positives among the 
enriched genes which are due to empty input, we only considered transcripts for which 




3.3.1 Protein extraction for western blot analysis 
 
Cells were washed with PBS, scraped off and centrifuged at 21,000 g for 15 s. After 
removing the PBS, cells were either frozen at -80oC or lysed directly in 
Radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris-Cl pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1 % IGEPAL® CA-630. 0.25 % sodium deoxycholate and freshly 
added protease inhibitor (Sigma-Aldrich, P2714). The lysate was then incubated on ice for 
30 min followed by centrifugation at 20,000 g for 30 min to remove the debris and 
insoluble proteins. 
The procedure to extract proteins from animal tissues was similarly conducted with minor 
modification: RIPA buffer also contained 0.1 % SDS. Tissues were homogenised in 
Dounce tissue grinder before incubation on ice.  
 
3.3.2 Protein quantification and preparation 
 
Protein concentration was determined using Bradford assay (Protein Assay Dye reagent 
concentrate, Bio-Rad 500-0006) according to manufacturer’s manual. Proteins were then 
diluted to either 1 µg/µl or 2 µg/µl with sample loading dye containing a final 
concentration of 0.03 M Tris-Cl pH6.8, 1 % SDS, 10 % glycerol, 0.1 % bromophenol blue 
and 5 % of β-mercaptoethanol. Proteins were then boiled for 5 min.  
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3.3.3 SDS-PAGE, western blot analysis and quantification 
 
Proteins were resolved by SDS-Polyacrylamide gels together with protein marker 
(PageRuler™ Plus Prestained Protein ladder, Life Technologies, 26620). Gels ranging from 
7.5 % to 12% (1.5 mm, 10 or 15 well combs) were casted with 30 % acrylamide (37.5:1 = 
acrylamide:bisacrylamide), 1 % ammoniumpersulfate (final concentrations), 0.1 % 
TEMED (N,N,N',N'-Tetramethylethylenediamine), 0.1 % SDS, separation buffer final 
concentration 0.375 M Tris-Cl pH 8.8 and stacking buffer final 0.125 M Tris-Cl pH 6.8. 
Proteins were separated in the gel soaked in running buffer (25 mM Tris, 0.192 mM 
glycine, 0.1 % SDS) at 30 mA per gel and blotted with wet transfer system either at 300 
mA for 90 min or 30 V overnight at 4°C in blotting buffer (25 mM Tris, 0.192 mM 
glycine, 20 % methanol). Absolute methanol was used to reactivate the membranes. 
Residual methanol was rinsed off with TBST (20 mM Tris-Cl pH7.4, 150 mM NaCl). The 
membranes were then blocked in either 5 % non-fat milk in TBST (20 mM Tris-Cl pH 7.4, 
150 mM NaCl, 0.1 % Tween 20) or in 1 % western blot reagent (Western Blocking 
Reagent, Roche 11 921 673 001) in TBST according to the antibodies used. Primary 
antibodies (Table 10) were incubated on the membrane for 1 hour at room temperature 
(RT) or overnight at 4°C. The membranes were washed for three times and each time for 5 
min with TBST. Secondary antibody was incubated for 1 hour at RT, the membrane was 
washed as that for primary antibodies. The membranes were developed using ECL or ECL 
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                        Table 10: Primary antibodies for western blot used in this study 
Antibody Company and catalogue Dilution 
Afg3l2 Kind gift from Prof. Langer 1:12,500 
Astrin, SPAG5 Proteintech, 14726-1-AP, 1:1000 
ATP5A1 Abcam, ab14748  1:1000 
calnexin Biotrend/ Assay Designs, SPA-860  1:2000 
CLUH (N-ter) Abcam, Ab178342  1:1000 
CLUH 05 Novus Biologicals, NB100-93305  1:500 
CLUH 06 Novus Biologicals, NB100-93306 1:1000 
COX1  Life Tecnlogies, A6403  
EIF3G Novus Biologicals, NB100-93298  1:1000 
FLAG Sigma-Aldrich, F3165  1:10,000 
GAPDH Chemicon/Millipore, MAB374  1:1000 
HADHA Abcam, ab54477 1:1000 
LC3 Novus Biologicals, NB100-2220  1:1000 
OGDH Proteintech, 15212-1-AP 1:1000 
OPA1 Abcam, ab42364  1:1000 
P62 PROGEN, GP62-C   1:1000 
pan-actin MAB1501R, Millipore  1:1000 
PCB Abcam, ab128952  1:1000 
POR Stressgen, OSA-300  1:1000 
RPL7 Novus Biologicals, NB100-2269  1:1000 
RPS6 Novus Biologicals, NB100-1595 1:1000 
S6K1Thr389 Cell Signaling, 9234 1:1000 
SDHA 
Molecular Probes, Life Technologies, A-
11142  
1:2000 
SKAP Sigma-Aldrich, SAB1103031  1:1000 
TOM20 Santa Cruz, sc-11415 1:2000 
UQCRC2 
Molecular Probes, Life Technologies, A-
11143 
1:2000 
Β-tubulin Sigma-Aldrich, T4026  1:10,000 
 
3.3.4 Cell fractionation  
 
Mouse tissues and MEFs were homogenized using automatic Potter S homogenizer 
(Sartorius, 8533024) in buffer containing 220 mM mannitol, 70 mM sucrose, 20 mM 
HEPES-NaOH pH7.4, 1 mM EDTA and 0.1 % BSA. Large debris was eliminated by 
centrifugation at 500 g at 4oC for 10 min. The supernatant was then centrifuged at 1,000 g 
to remove the nuclear fraction. Mitochondria were obtained by centrifugation at 8,000 g 
for 10 min. The resulting supernatant was then centrifuged at 20,000 g for 10 min. The 
supernatant was further separated by ultracentrifugation at 170,000 g for 45 min. Light 
membranes were harvested by dissolving the pellet in buffer containing 50 mM Tris-Cl pH 
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7.4, 150 mM NaCl, 1 mM EDTA pH 8, 1 % IGEPAL® CA-630, 0.25 % sodium 
deoxycholate and protease inhibitor cocktail. The protein concentration was measured with 
Bio-Rad Protein Assay (Bio-Rad) and same concentration of protein was loaded from each 
fraction. 
 
3.3.5 Sucrose gradient and polysome profiling  
 
All procedures were carried out in strictly RNase free environment. Samples were kept 
cool at all time unless stated otherwise. HeLa or NSC34 cells were plated one night before 
and harvested at 70-80 % of confluence. Polysomes were stalled by treating the cells with 
100 µg/ml of cycloheximide (Sigma-Aldrich, C4859) for 15 min in the cell incubator. 
Cells were washed twice and scraped in DPBS containing cycloheximide at 4°C. After 
pelleting cells at 21,000 g for 15 s, the pellet was lysed in buffer containing 20 mM Tris-Cl 
pH 7.4, 30 mM KCl, 0.5 % Triton X-100, 2 mM DTT, 1 mg/ml heparin, 100 µg/ml 
cycloheximide and 0.16 unit/ml RNasin® Plus RNase Inhibitor (Promega, N2615). The 
lysates were then loaded onto a 7–47 % (mol wt/vol) continuous sucrose gradient and 
centrifuged at 97,658 g for 3 h at 4°C in a Beckman SW41 rotor.  
Sucrose gradient was prepared with Gradient Master (BioComp Instruments) at RT 
according to manufacture´s instruction. Level of 47 % of sucrose was labelled by inserting 
the tube into the aluminium gig and marking the top edge (for short cap) of the gig. 47 % 
sucrose was pipetted into the tube first and 7 % sucrose was then carefully added on top of 
the 47 % sucrose without disturbing the interface. After placing the short cap on the tube, 
extra sucrose was pipetted off from the cap. The level of the gradient master was adjusted 
and the gradients were prepared by selecting short cap and 7-47% on the menu. After 
gradient master stop rotating and returned to the starting position, cap was removed and 
500 µl of sucrose was taken from the top of the gradient. Keep the sucrose gradient at 4oC 
until use.   
For polysome profiling, fractions were monitored at 254 nm and collected using ISCO 
fractionation system (ISCO, Lincoln, NE). For western blot analysis, the same volume of 
samples from each fraction was loaded on the SDS-PAGE.  
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3.3.6 Metabolic labeling and biotinylation of the newly synthesised proteins 
 
MEFs were cultured one night before the experiment. MEFs were washed twice with 5 ml 
methionine free media containing DMEM (L-methionine, L-Cystine free, Life 
Technologies, 21013-024), supplemented with 10 % dialysed serum, 2 % penicillin-
streptomycin, 1 mM pyruvate, 1x non-essential amino acid and 2 mM L-.glutamine. Cells 
were then incubated with methionine free media for 30 min in the cell incubator. 
Afterwards, the media was replaced with metabolic labeling media containing methionine 
free media supplemented with L-azidohomoalaine (AHA, Click-iT™, Life Technologies, 
C10102) and incubated for 1 hour. Treated cells were then washed with cold PBS for three 
times, scraped off and centrifuged down at 21,000 g for 15 s. Cell pellets were lysed with 
buffer containing 50 mM Tris-Cl, pH 8.0 and 1 % SDS and lysed for 30 min in a head-to-
toe shaker at 4oC. Cell lysates were then sonicated and centrifuged for 10 min at 15,000 g 
at 4°C. Protein concentrations were estimated using BCA protein assay reagent (Life 
Technologies, 23255). 
Biotinylation of AHA labeled proteins was performed using Click-iT™ protein reaction 
buffer kit (Life Technologies, C10276). Up to 200 µg cell lysates in 50 µl were subjected 
to Click-iT™ azide/alkyne reaction according to manufacturer´s instruction. The resulting 
protein pellets were dissolved in 200 µl of IP150 buffer including 150 mM NaCl, 20 mM 
Tris-Cl, pH7.5, 0.3 % IGEPAL® CA-630, 1 mM EDTA, and fresh 1 mM DTT 
supplemented with protease inhibitor cocktails. Dissolved proteins were incubated with 50 
µl of Dynabeads® M-280 Streptavidin (Life Technologies, 11205D) for overnight at 4oC. 
Dynabeads were washed for 5 times with 1 ml of IP350 (350 mM NaCl, 20 mM Tris-Cl, 
pH7.5, 1 mM EDTA, 0.3 % NP-40, and fresh 1 mM DTT). The beads were then 
resuspended in SDS sample buffer, mixed thoroughly with vortex for 1 min. Proteins were 
denature by boiling for 10 min and the supernatants were then subjected to western blotting.  
 
3.4 Obtaining mouse tissues  
 
Mice at different ages were prepared by crossing full body Afg3l2 flox/flox lines. The 
organs were harvested according to stardard animal procedures. E18.5 mice were obtained 
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by C-section.Organs were frozen on dry ice and stored at -80oC after harvesting till use. 
 
3.5 Statistical analysis 
Statistical analyses were performed using unpaired Student’s t-test. Error bars show 
standard deviations.  
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4.1 CLUH is coregulated with genes encoding mitochondrial proteins and involved 
in translation  
 
In order to understand the function of CLUH in mammalian system, we examined genes 
that coregulate with Cluh/CLUH in mouse and human. This was achieved by analysing 
the publicly available microarray data from different samples under different conditions 
(Sardiello, Palmieri et al. 2009). Interestingly, both mouse/human Cluh/CLUH are 
significantly coexpressed with two clusters of genes. One includes genes involved in 
RNP complex biogenesis, ribosome biogenesis and the other is mitochondrial genes 
involved in electron transport chain, oxidative phosphorylation, TCA cycle, and 
generation of small metabolites and energy (Figure 10A and B). The analysis was 
performed by Dr. Marco Sardiello from Jan and Dan Duncan Neurological Reseach 
Institute in Houston, USA.    
 
 
Figure 10: Coregulation analysis of CLUH/Cluh. (A) Analysis of Gene Ontology of the group 
of genes coexpressed with CLUH/Cluh. The fold enrichment for the biological process Gene 
Ontology terms is shown (P < 10-4). The green dotted line corresponds to fold enrichment of 1. 
(B) Cytoscape-generated Cluh gene regulatory network. Genes encoding mitochondrial- and 
ribosomal biogenesis- related proteins are highlighted and are connected by blue lines whose 
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4.2 CLUH is an RNA binding protein 
 
Based on the coexpression analysis of the CLUH gene regulatory network and the 
finding that yeast Clu was identified as a component of eIF3 (Vornlocher, Hanachi et al. 
1999), we hypothesised that CLUH could be an important mediator connecting 
cytosolic translation to mitochondrial biogenesis. One possibility is that, CLUH could 
act as an mRNA binding protein that binds to NEMP mRNAs. This hypothesis could 
also explain the reduction of steady state protein levels of CVα (α subunit of complex V) 
and PDH (pyruvate dehydrogenase) in Drosophila Clu mutant (Cox and Spradling 
2009).  
To assess if CLUH is an RNA binding protein, UV crosslinking immunoprecipitation 
(CLIP) was employed: briefly, HeLa cells were exposed to 300 mJ of UV at 254 nm in 
order to generate a covalent bond between proteins and mRNAs only when they are at 
close proximity (i.e. interacting) (Darnell 2012). This was followed by DNase/RNaseI 
digestions of the cell lysate. Different concentrations of RNase I can generate different 
RNA-protein complexes determined by the length of the RNAs. The endogenous RNP 
complexes were subsequently immunoprecipitated and washed extensively to eliminate 
the unspecifically bound proteins and RNAs. Antibodies against Afg3l1, the subunit of 
mAAA-protease in the mouse were used as a control IgG for RNA binding specificity. 
The nucleic acids were then radio-labeled at their 5´-hydroxyl group in a reaction 
catalysed by T4 polynucleotide kinase from [γ-32P] ATP. The RNP complex was then 
separated from the other proteins and RNAs by means of SDS-PAGE.  
CLUH could be successfully precipitated with antibodies against the endogenous 
CLUH (Figure 11). Moreover, at its corresponding position in the autoradiogram, a 
discrete RNA band appeared with high concentration of RNase I (Figure 11, shown 
with arrow), and this band became an upward smear with low concentration of RNase I 
(Figure 11, shown with bracket). Without UV crosslinking, no RNAs could be pulled 
down with CLUH. The smearing effect is essential to demonstrate that the nucleic acids 
bound to CLUH are RNA, not DNA since this phenomenon is RNase I dependent.  
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Figure 11: CLUH is an RNA binding protein. (A) CLIP with anti-CLUH antibodies in HeLa 
lysate after crosslinking with 300mJ UV. Two different concentrations of RNase I were used to 
distinguish the difference between RNA and DNA species. Lower panel shows the western blot 
of the corresponding experiment showing the efficiency of immunoprecipitation. Arrow 
indicates the CLUH-nucleic acid complexes whereas the bracket shows the smear formed by 
RNase I digestion. 
 
In order to confirm the above finding and reduce the chance of obtaining false positive 
result, different system was adopted for CLIP analysis. HEK 293T cell lines were 
generated either stably expressing CLUH tagged with FLAG at its C-terminus or empty 
FLAG (see more about this cell line below). Expression of these proteins was induced 
with tetracycline. In contrast to CLIP in HeLa cells, this system allows the utilisation of 
same antibodies for control and overexpressed proteins.  
CLIP experiment was performed with minor modification: 400 mJ of UV at 254 nm 
was applied to crosslink the protein-RNA complex instead of 300 mJ based on the 
optimisation experiments conducted previously. Overexpressed CLUH could be 
immunoprecipitated with anti-FLAG antibodies (Figure 12, lower panel). After UV 
crosslinking, the amount of immunoprecipitated CLUH was considerably less than that 
without UV. However, no nucleic acid signals could be seen for the non-crosslinked 
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sample. Overexpressed CLUH could be crosslinked to RNA. The RNA signal appeared 
at the expected size of CLUH (Figure 12, shown with arrow) and smears with RNase I 
treatment (Figure 12, shown with bracket). 
Taken together, these experiments provide strong evidences that the mammalian CLUH 
is undoubtedly an RNA binding protein.  
 
Figure 12: CLIP with anti-FLAG in HEK 293T cells overexpressing CLUH-FLAG or 
empty FLAG. Cells were induced for 24 hours with tetracycline. Lower panel is the western 
blot of the corresponding experiment showing the efficiency of immunoprecipitation. Arrow 
indicates the CLUH-nucleic acid complexes whereas the bracket shows the smear formed by 
RNase I digestion. 
 
4.3 CLUH preferentially binds to mRNAs encoded in the nucleus for 
mitochondrial proteins  
 
Next, we ought to find out what are the RNAs that are bound by CLUH. We 
hypothesised that NEMPs mRNAs that were highly coexpressed with CLUH could be 
the potential targets. Consequently, CLIP experiments with HeLa cells were conducted 
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to immunoprecipitate (RNA immunoprecipitation, or RIP) the endogenous CLUH but 
without RNase I treatment. After immunoprecipitation, RNAs were purified and 
extracted with proteinase K and phenol-chloroform. The final RNA products were 
reverse transcribed into cDNAs and analysed with quantitative reverse transcription 
PCR (qRT-PCR). Several genes were tested based on their coexpression relationship 
with CLUH: OGDH, ATP5A1, GOT2, OPA1, SPG7, COX10 and AFG3L2. Three 
housekeeping genes were selected as controls: ACTIN, GAPDH and TBP.  
Intriguingly, these mRNAs were all enriched by CLUH immunoprecipitation when 
compare to control IgG (anti-Afg3l1) with OGDH being the most enriched and AFG3L2 
the least (Figure 13A and B). There might be a subtle enrichment of actin by CLUH but 
not with the other two housekeeping controls. It is worth mentioning that the 
enrichments of these genes measured by qRT-PCR for different genes varies from one 
experiment to another, this is due to the fact that this experiment includes many steps 
that could affect the final RNA/cDNA quality, namely: quality of antibodies, 




Figure 13: mRNAs bound by CLUH with qRT-PCR. (A) The average enrichment for each 
mRNA. (B) The plot of fold enrichment from individual experiment for each gene. Fold 
enrichment is compared with the immunoprecipitation with anti-Afg3l1 antibody. n≥3 
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4.4 Global analysis of the mRNAs bounds by CLUH  
 
To gain a comprehensive view of the mRNA targets of CLUH, and confirm that CLUH 
binds to NEMP mRNAs specifically, next generation RNA sequencing were performed 
on mRNAs pulled down with CLUH. As before, after UV irradiation, endogenous 
CLUH was captured together with the RNA crosslinked to CLUH. For this experiment, 
RNase I treatment was also omitted preceding immunoprecipitation. The RNA was 
extracted and purified as well as the input RNA (total transcriptome). Three biological 
replicates were conducted and the RNA was submitted to Cologne Center for Genomics 
(CCG) to carry out next generation sequencing. The analysis and the quality control of 
the sequencing data were performed by the Bioinformatics facility in CECAD, Cologne 
(See appendix, Table 16). 
RNAs that were enriched for more than five times with a P value of less than 0.01 in 
CLUH-RIP against Afg3l1-RIP were chosen for further bioinformatics analysis. There 
were 288 genes in total in this list, 272 encode for proteins, 16 fall in the class of 
miRNA (one miRNA is enriched 41.01 times), pseudogene and long non-coding RNA. 
87.9 % of protein coding mRNAs belong to the NEMPs (239 mRNAs) (Figure 14) (Full 
list of NEMPS mRNA can be found in the appendix Table 17). Among the top 40 genes 
enriched by CLUH (Table 11), only one encodes for a cytosolic protein: SPAG5 
(encoding for astrin). The 33 non-mitochondrial mRNAs bound by CLUH encode for 




R e s u l t s  | 62 
 
 
Figure 14: Category of the RNAs bound by CLUH. Only RNAs enriched more than five 
times with a P value of less than 0.01 in CLUH-RIP against IgG-RIP were chosen for analysis. 
NEMP, nuclear encoded mitochondrial protein.  
 
The protein products of CLUH target mRNAs were found to participate in diverse 
mitochondrial pathways identified by Ingenuity Pathway Analysis (IPA) (Table 13 and 
14), ranging from branched-chain amino acid degradation, oxidative phosphorylation, 
tRNA charging to mitochondrial quality control. Interestingly, the ten most significant 
canonical pathways are closely related to mitochondrial energy production from 
different sources: degradation of branched-chain amino acids: valine (glucogenic, to 
succinyl-CoA), leucine (ketogetic, to acetyl-CoA) and isoleucine (glucogenic and 
ketogenic, to both succinyl-CoA and acetyl-CoA). Acetyl-CoA enters the TCA cycle 
whereas succinyl-CoA is an important intermediate of the TCA cycle.  
In fact, almost half enzymes involved in branched-chain amino acids (leucine, 
isoleucine and valine) degradation are encoded by mRNAs bound by CLUH (20 from 
IPA compare to a total of 46 genes involved in these pathways listed in KEGG, Figure 
15). More strikingly, beside branched-chain amino acids, other amino acid degradation 
pathways could also be found on this list: tryptophan, methionine, alanine, arginine, 
aspartate, glutamine, phenylalanine, proline, lysine, and glycine. Genes involved in 
degradation pathway for these amino acids are not present (with our setting criteria, 
genes enriched for more than five times with a P value less than 0.01): cysteine, serine, 
threonine and tyrosine. Interestingly, the mRNAs of eight out of 19 aminoacyl tRNA 
synthases were also found to be bound by CLUH: PARS2 (prolyl-), TARS2 (threonyl-), 
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IARS2 (isoleucyl-), FARS2 (phenylalanyl-), CARS2 (cysteinyl-), LARS2 (leucyl-), 
EARS2 (glutamyl-) and DARS2 (aspartyl-).  
The mRNAs of all enzymes involved in pyruvate conversion to acetyl-CoA were targets 
of CLUH. More than half of the components of TCA cycle were CLUH targets, apart 
from the immediate enzymes involved in the conversion to succinate, α-ketoglutarate 
and citrate (Figure 16).  
Among the CLUH targets, there are also components belonging to oxidative 
phosphorylation (Figure 17). CLUH binds to the mRNAs of seven subunits of complex 
I (three from NADH dehydrogenase (ubiquinone) 1 alpha subcomplex: NDUFA10, 
NDUFA9 and NDUFAB1, three from NADH dehydrogenase (ubiquinone) Fe-S protein: 
NDUFS1, NDUFS2, NDUFS7 and one from NADH dehydrogenase (ubiquinone) 
flavoprotein: NDUFV1 and one assembly factor NDUFAF5). The mRNAs of all four 
subunits of complex II or succinate dehydrogenase (SDHA, SDHB, SDHC and SDHD, 
SDHA being the most enriched among the four) were found to be bound by CLUH. For 
complex III, the targets were the core protein ISP (UQCRFSL1) or Rieske iron-sulfur 
protein and QCR2. Only assembly factor COX15 from complex IV was found. Whereas 
in complex V, ATP5A1 and the assembly factors ATPAF1, TMEM70 and ATPAF2 were 
found to bind to CLUH (Figure 17). 
There are also genes involved in mitochondrial quality control and dynamics: PINK1, 
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Table 11: Top 40 genes bound by CLUH. FC, fold Change. * indicates non-mitochondrial. 
FC Symbol Description 
57,35 GFM1 G elongation factor, mitochondrial 1 
57,35 PCCA propionyl CoA carboxylase, alpha polypeptide 
43,97 HIBADH 3-hydroxyisobutyrate dehydrogenase 
42,97 ALDH6A1 aldehyde dehydrogenase 6 family, member A1 
41,85 PCB pyruvate carboxylase 
41,1 LACTB lactamase, beta 
41,06 OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) 
39,82 PINK1 PTEN induced putative kinase 1 
39,4 SPAG5* sperm associated antigen 5 
39,12 LARS2 leucyl-tRNA synthetase 2, mitochondrial 
38,73 PMPCA peptidase (mitochondrial processing) alpha 
38,23 DARS2 aspartyl-tRNA synthetase 2, mitochondrial 
37,78 GHITM growth hormone inducible transmembrane protein 
37,77 HSPA9 heat shock 70kDa protein 9 (mortalin) 
37,6 ATPAF2 ATP synthase mitochondrial F1 complex assembly factor 2 
37,26 CHDH choline dehydrogenase 
37,06 PPA2 pyrophosphatase (inorganic) 2 
36,76 DLAT dihydrolipoamide S-acetyltransferase 
35,27 CPT2 carnitine palmitoyltransferase 2 
35,22 ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain 
34,22 ALDH18A
1 
aldehyde dehydrogenase 18 family, member A1 
33,05 MRPL16 mitochondrial ribosomal protein L16 
32,86 ACSF2 acyl-CoA synthetase family member 2 
31,17 IARS2 isoleucyl-tRNAsynthetase 2, mitochondrial 
31,02 SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 
30,99 ALAS1 aminolevulinate, delta-, synthase 1 
30,93 NNT nicotinamide nucleotide transhydrogenase 
30,3 ETFDH electron-transferring-flavoprotein dehydrogenase 
29,64 MUT methylmalonyl CoA mutase 
28,76 AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1 
26,94 PITRM1 Pitrilysin metallopeptidase 1 
26,16 IMMT inner membrane protein, mitochondrial 
26,04 LRPPRC leucine-rich pentatricopeptide repeat containing 
25,98 ALDH7A1 aldehyde dehydrogenase 7 family, member A1 
25,24 ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 7 
25,24 GBAS glioblastoma amplified sequence 
24,81 CKMT1B;
CKMT1A 
creatine kinase, mitochondrial 1A 
24,28 DLD dihydrolipoamide dehydrogenase 
24,04 ABCB8 ATP-binding cassette, sub-family B (MDR/TAP), member 8 
23,94 BDH1 3-hydroxybutyrate dehydrogenase, type 1 
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Table 12: Nuclear-encoded mRNAs for non-mitochondrial proteins. 
FC Symbol Cellular Location Description 
39,44 SPAG5 Cytosol sperm associated antigen 5 
23,48 NEK11 Nucleus NIMA-related kinase 11 
16,39 GALK2;LOC102723 Cytosol galactokinase 2 
16,03 HLTF Nucleus helicase-like transcription factor 
12,95 JSRP1 Nucleus , Cytosol junctional sarcoplasmic reticulum 
protein 1 
12,68 TMEM69 Plasma Membrane transmembrane protein 69 
11,96 CCRN4L Nucleus, Cytosol CCR4 carbon catabolite repression 
4-like (S. cerevisiae) 
10,87 NIPSNAP3A Nucleus, Cytosol nipsnap homolog 3A (C. elegans) 
9,16 GTPBP6 Nucleus ? GTP binding protein 6 (putative) 
8,2 DHRS4;DHRS4L2 Extracellular, 
Mitochondrion 
dehydrogenase/reductase (SDR 
family) member 4 like 2 
7,76 MLF2 Cytosol myeloid leukemia factor 2 
7,49 GAS5-AS1 non-protein coding GAS5 antisense RNA 1 
7,34 ANGEL2 Cytosol ? angel homolog 2 (Drosophila) 
7,31 C1orf53 ? chromosome 1 open reading frame 
53 7,07 RNLS Extracellular renalase, FAD-dependent amine 
oxidase 
6,42 SLC30A9 Nucleus, Cytoskeleton solute carrier family 30 (zinc 
transporter), member 9 
6,28 VPS37D Endosome vacuolar protein sorting 37 homolog 
D (S. cerevisiae) 6,21 PRSS57 Extracellular protease, s r ne, 57 
6,2 HNRNPA2B1 Nucleus heterogeneous nuclear 
ribonucleoprotein A2/B1 
6,19 RPUSD2 Cytosol RNA pseudouridylate synthase 
domain containing 2 
6,07 AKR1B1 Extracellular, Cytosol, 
Nucleus 
aldo-ketoreductase family 1, 
member B1 (aldose reductase) 
6,01 RPP40 Nucleus ribonuclease P/MRP 40kDa subunit 
5,88 WDR13 Nucleus, Cytosol WD repeat domain 13 
5,87 ABHD16A ? abhydrolase domain containing 16A 
5,87 PCDH12 Plasma Membrane protocadherin 
5,78 PCED1B ? PC-esterase domain containing 1B 
5,74 MTM1 Endsome, Plasm Membrane myotubularin 1 
5,74 PEX3 ER, Peroxisome peroxisomal biogenesis factor 3 
5,69 MBLAC2 Cytosol metallo-beta-lactamase domain 
containing 2 
5,6 PRMT6 Nucleus protein arginine methyltransferase 6 
5,58 AIMP2 Cytosol 
aminoacyl tRNA synthetase 
complex-interacting multifunctional 
protein 2 
5,48 INHBE Extracellular inhibin, beta E 
5,04 PAX9 Nucleus paired box 9 
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Table 13: Top 20 canonical pathways identified by Ingenuity Pathway Analysis. 
Canonical Pathways -log(p-value) Molecules 



























Leucine Degradation I 9.48E00 BCAT2,AUH,MCCC1,IVD,ACADM,MCCC2 
Fatty Acid α-oxidation 9.28E00 TMLHE,ALDH4A1,ALDH1B1,ALDH2,BCO2,ALDH
9A1,ALDH7A1 











tRNA Charging 7.56E00 PARS2,TARS2,IARS2,FARS2,CARS2,LARS2,EARS2,
DARS2 
Ketolysis 7.41E00 HADHB,BDH1,ACAT1,OXCT1,HADHA 
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Table 14: The top 17 function and diseases pathways identified with Ingenuity Pathway 
Analysis 
Diseasesor Functions p-Value Molecules 







































chain amino acids 
5.56E-15 ALDH6A1,BCAT2,BCKDHA,BCKDHB,BCKDK,HIBADH,IVD,
MCCC2 

































Leigh syndrome 1.56E-09 COX15,FOXRED1,LRPPRC,NDUFA10,NDUFA9,NDUFS7,PD
HA1,SDHA 




Figure 15: Highlight of protein products of mRNAs bound by CLUH involved in 
branched-chain amino acids metabolism pathway. Created by KEGG pathway. 
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Figure 16: Highlight of protein products of mRNAs bound by CLUH involved in TCA 
cycle. See Figure 15 for key. Created by KEGG pathway. 
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Figure 17: Highlight of protein products of mRNAs bound by CLUH involved in oxidative 
phosphorylation. See Figure 15 for key. Created by KEGG pathway. 
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4.5 The mRNA of the cytosolic protein astrin is bound by CLUH 
 
Among many of the highly enriched mRNAs bound by CLUH (Table 11), one mRNA 
of a cytosolic protein caught our attention: SPAG5. Work carried out in our lab has 
identified the protein product of this mRNA to be an interactor of CLUH (Désirée 
Schatton, personal communication). Astrin is involved in mitosis and the mTOR 
pathway (Mack and Compton 2001; Thedieck, Holzwarth et al. 2013). SPAG5 mRNA 
binding by CLUH was also validated with qRT-PCR performed on RNA 




Figure 18: Validation of SPAG5 bound by CLUH. (A) The average enrichment for each 
mRNA. (B) The plot of fold enrichment from individual experiment for each gene. Fold 
enrichment is compared with the immunoprecipitation with anti-Afg3l1 antibody. n≥3 
 
4.6 CLUH affects the protein level of its mRNA targets  
 
mRNA binding proteins can facilitate the transport of mRNAs to their destinations or 
regulate the half-life and translation of mRNAs in response to cellular cues or anchoring 
mRNAs to their destination. Therefore, we started with investigating the possible role of 
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CLUH in regulating translation of its target mRNAs. First, we evaluated if CLUH 
affects the steady state protein level of its targets. Dr. Henriette Hansen in our lab had 
previously generated the immortalized MEFs from wildtype and Cluh knockout 
embryos at E14.5 of age by C-section. 
The protein level of some targets were exaimined from two pairs of wildtype and Cluh 
knockout MEFs: OGDH, ATP5A1, AFG3L2, OPA1, SDHA and UQCRC2 (Figure 19 
A). Pan-actin and GAPDH was used here as a loading control, TOM20 was used as a 
control for mitochondrial mass. The protein levels of the tested targets were reduced 
with the exception of SDHA and UQCRC2. However, the levels of SDHA and 
UQCRC2 were significantly decreased in the liver of CLUH knockout (personal 
communication with Désirée Schatton). Mitochondrial mass, did not seem to be altered 
as indicated by TOM20.  
Since the decrease of transcript levels can also lead to reduction of the respective 
protein level, initial investigation was conducted on the transcript level of Atp5a1 and 
Afg3l2 in these MEFs using qRT-PCR. The mRNA levels of tested CLUH targets 
remain unchanged with the notable exception of Atp5a1 (Figure 19 B, more qRT-PCR 
data can be found from Gao et al. 2014, conducted by Désirée Schatton), hinting to a 
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Figure 19: CLUH affects the protein levels of its target mRNAs. (A) Four immortalised 
MEF lines were generated by Dr. Hansen, E3 and E25 are the wildtypes whereas E6 and E8 are 
the Cluh knockout. The protein levels of CLUH targets were tested by western blots, pan-actin 
and GAPDH were used as loading controls. (B) The mRNA levels of Atp5a1, and Afg3l2 were 
measured with q RT-PCR with Gapdh as an endogenous control.  
 
4.7 CLUH overexpression upregulates the protein level of some of its targets  
 
Doed CLUH overexpression lead to the opposite effect in contrast to Cluh knockout? 
To address this, CLUH with a C-terminal FLAG tag was overexpressed by induction of 
HEK 293T with 1 µg/ml of tetracycline for different time. Four target proteins were 
selected here to examine their response to CLUH overexpression: ATP5A1, HADHA, 
astrin and OPA1. However they display three different responses to the increase of 
CLUH: ATP5A1 remains mostly unchanged while OPA1 is increased, and to our 
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surprise, HADHA is decreased (Figure 20). When comparing the expression level of 
these proteins at different time points, a non-linear relationship between CLUH 
expression level and the level of its targets was observed (see OPA1 from time 0 to 16 h 
to 48 h). On the other hand, CLUH cytoslic target astrin (the upper band) is in a linear 
relationship with CLUH.  
 
Figure 20: CLUH overexpression induces different target responses. (A) CLUH-FLAG and 
empty FLAG were expressed with induction of 1 µg/ml of tetracycline for different times points. 
Same volume of EtOH was added to HEK 293T as a control (final concentration 0.18 %). n=3, 
see appendix Figure 34 for the other two repeats. 
 
4.8 Global cytosolic translation is unaffected in the absence of CLUH 
 
Since yeast Clu1 has been identified to be associated with the translation initiation 
factor 3 (Vornlocher, Hanachi et al. 1999), it is crucial to examine if the reduction in 
steady state protein levels in CLUH deficient cells is due to a general defect in 
translation. Two approaches were undertaken here: first, radioactive 35S methionine 
/cysteine was fed to cells in order to incorporate it into newly sythesised proteins. The 
total protein lysate was then resolved by SDS-PAGE and revealed with autoradiogram 
(Figure 21 A and C). Secondly, cells were treated with cycloheximide, a translation 
elongation inhibitor in order to stabilise the 80S and the polysome, followed by mild 
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cell lysis to minimise the damage to the integrity of the ribosomes. The lysate was then 
subjected to sucrose gradient ultracenrifugation for the separation of 40S, 60S, 80S and 
polysome (Figure 21 B and D). The first method provides a general impression as to 
whether the translation is impaired, whereas polysome profiling provides higher 
resolution at which step that translation might be affected.  
The two methods were used in parallel in cells either transiently (knockdown for 72 
hours with different siRNA combinations in murine NSC34 cells, Figure 21A and B) or 
permanently (MEFs, Figure 21C and D) depleted of CLUH to exclude compensatory 
cellular responses from the loss of CLUH. There were no major changes of newly 
synthesised proteins or in the translation machinery: equal amount of proteins were 
synthesised at different time points and the traits of 40S, 60S, 80S and polysomes 
appeared to be almost identical between control and CLUH depleted cells. These results 
are consistent with the studies in yeast (Vornlocher, Hanachi et al. 1999) and the 
observation of normal growth rate and viability in S. cerevisiae (Fields, Conrad et al. 
1998). In conclusion, CLUH depletion/deletion does not affect the cytosolic translation 
in general, therefore hinted that CLUH may act as a specific translation regulator for its 
targets. 
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Figure 21: Global cellular translation is unaffected in the absence of CLUH. (A and C) 
Autoradiogram of in vitro translation assay in MEFs and NSC34 cells, showed no major change 
in the Cluh knockout and knockdown, respectively. (B and D) Polysome profilings consistently 
showed no obvious alterations in general translation machinery. 
 
R e s u l t s  | 77 
 
4.9 Translation of CLUH targets is affected  
 
Since the steady state levels of CLUH targets were significantly reduced. We propose 
that CLUH is a positive translational regulator of its target mRNAs. That is in the 
absence of CLUH, translation of its targets is affected. To assess this question, 
methionine analogues L-azidohomoalanine (AHA) was used to incorporate into the 
nascent proteins similar to in vitro translation assay mentioned above. This was 
followed by copper catalysed click reaction that adds biotin to AHA modified proteins 
(Figure 22A). The nascent biotinylated proteins were then captured with magnetic beads 
coupled with streptavidin. To determine the translation of a particular protein, two 
parameters must be taken into account: the amount of protein being translated and its 
respective mRNA levels. The transcript levels of the tested targets Sdha (0.66), Atp5a1 
(0.48) and Ogdh (0.49) were reduced in Cluh knockout MEFs compared to the control. 
So were the target protein levels. However, the reduction of transcription could not be 
responsible for the reduction of their proteins levels for SDHA, ATP5A1 and OGDH. 
Moreover, the non-target mitochondrial control of TOM20 and housekeeping GAPDH 
were not affected. Therefore, CLUH is likely to affect the translation of SDHA, 
ATP5A1 and OGDH specifically. However, the exact mechanism needs to be 
elucidated further. The next step would be to conduct a systematic analysis to 
understand if the translation of all targets is affected, this can be achieved by using 
either ribosome profiling or polysome profiling coupled with RNA-sequencing. 
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Figure 22: The translation of CLUH targets is affected in the absence of CLUH. (A) Brief 
illustration of the experimental procedure. (B) Western blot of input, flowthrough and elution 
decorated with antibodies against the protein products of different CLUH targets, GAPDH is a 
cytosolic non-target control and TOM20 is a mitochondrial non-target control. (C) 
Quantification of the newly synthesised proteins (elution) of knockout against wildtype. 
Quantification of transcript levels measured by qRT-PCR. The transcripts were normalized to 
GAPDH. The normalised transcripts level in knockout was compared to wildtype. Translational 
arrest was estimated by normalizing the protein level to the mRNA level. n=1 
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4.10 Localisation of CLUH 
 
CLUH does not contain any mitochondrial targeting signal (MTS) when analysed with 
Predotar, TargetP and MitoProt (Table 15). Moreover, it is a cytosolic protein from 
various immunocytochemistry studies performed in different organisms. Intriguingly, 
Clu particles are found to be at the close proximity to mitochondria in flies (Cox and 
Spradling 2009). Since CLUH binds to the mRNAs of NEMP and might regulate their 
translation specifically, this suggests that it is possible that a small portion of CLUH can 
be located outside or close to mitochondria in order to deliver the mRNAs/proteins 
close to mitochondria. Therefore, we investigated if a population of CLUH proteins is 
located close to mitochondria.  
 
Table 15 : Mitochondrial proteins prediction with different online tools for CLUH. 
Predotar 
Mitochondrial ER Elsewhere Prediction 
0,00 0,01 0,99 none 
TargetP 1.1 
mTP SP other Loc RC 
0,063 0,062 0,937 - 1 
MitoProt II 
Probability of export to mitochondria 
0,023 
mTp, mitochondrial targeting peptide; SP, signal peptide; Loc, prediction of localization; RC, 
reliability class, from 1 to 5, with 1 being the most reliable. 
 
To examine the subcellular localisation of CLUH, we employed immunocytochemistry 
with specific antibody against human CLUH in HeLa Cells. CLUH (red) in HeLa cells 
formed puncta/granular structure in the cytoplasm with no obvious colocalisation to 
mitochondria (anti-COX1, green) in culturing conditions containing either high glucose 
or galactose (condition to enhance OXPHOS) (Figure 23). Sometimes, orange colors 
were observed in the merged images that indicating a colocalisation of CLUH with 
mitochondria. However, it is not clear if this is a genuine colocalisation, because CLUH 
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is an abundant cytosolic protein, it may be present in a similar space with mitochondria 
without colocalising with mitochondria. 
 
Figure 23 : CLUH does not show obvious colocalisation with mitochondria in 
immuocytochemistry. HeLa cells were cultured either with complete or galactose media for 72 
hours. CLUH was decorated with anti-CLUH 06 (c-ter) antibody, red. Mitochondria were 
stained with anti-COX1, green, and nuclei with DAPI, blue. Bar: 20 µM. 
 
To validate these data, crude cell fractionation was performed to enrich mitochondria 
and separate cytosol from the light membrane fraction (Figure 24). Mitochondria were 
enriched, as indicated by SDHA. However, this fraction was contaminated with ER, as 
indicated by the presence of POR. The majority of CLUH was present in the light 
membrane fraction, which also contained ribosomes (RPL7) and ER membranes (POR). 
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However, a small portion of CLUH was observed in the mitochondrial fraction in 
mouse liver, brain (Figure 24A), and cultured primary MEFs (Figure 24B). The 
ribosomal large subunit RPL7 shared a similar localisation pattern to CLUH in both 
brain and liver. In the crude fractionation of Cluh knockout primary MEFs, CLUH was 
absent at the expected size (Figure 24B).  
At this point, it is impossible to distinguish if CLUH is a genuine protein that resides 
outside of mitochondria or if it is a contamination rooted from the failure of obtaining 
an absolute mitochondrial fraction completely devoid of ER components.  
Considering that CLUH might associate with the translation initiation factor 
(Vornlocher, Hanachi et al. 1999), polysome profiling was performed to evaluate 
whether CLUH peaks with any of the translational components such as EIF3G, RPS6 
and RPL7 (Figure 24C). RPS6, a component of small ribosome was located in the 
expected fractions: the 40S, 80S and the polysomes. RPL7, the component of the large 
ribosome was located in the 80S and polysomes. The subunit of translation initiation 
factor EIF3G cofractionated with 40S and 60S but was depleted from the polysome 
fractions. Despite the fact that the majority of CLUH was present in the light membrane 
fraction in the crude fractionation, CLUH peaked at the non-ribosomal fractions. Some 
CLUH might form heavier complexes, which ccould be seen in the later fractions. In 
conclusion, this hinted that CLUH is not a main component of the translation machinery, 
which is in line with the evidence that yeast Clu and mammalian CLUH are not 
essential components of eIF3 complex and is not essential for general translation 
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Figure 24: A small portion of CLUH is found to co-fractionate with mitochondria. (A) 
Crude cellular fractionation of murine brain and liver. Anti-CLUH (N-ter, CLUH 05) was used 
to decorate the whole membrane. SDHA, β-tub and RPL7 were used as a cocktail. POR was 
probed afterwards. * indicates that POR at its expected size (B) Crude cellular fractionation of 
primary MEFs. Arrow indicates CLUH at the expected size. Asterisk indicates the POR at 
expected size, the other band is the leftover signal from SDHA. (C) Polysome profiling of cell 
lysate from HeLa. The upper part shows the UV absorbance whereas the lower part, the western 
blot of corresponding fractions probed with translation related markers.  
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4.11 CLUH level in response to galactose and acetoacetate treatment 
 
CLUH binds to the mRNAs of NEMPs and regulates their translation by an unknown 
mechanism, but is CLUH an essential component for mitochondrial biogenesis? ATP 
can be produced from different sources, for example: amino acids, fatty acids or glucose. 
As mentioned above, CLUH binds to many mRNAs involved in energy production from 
different carbon sources. Routine culturing media contain high concentrations of 
glucose (4.5g/L), which renders the cells to rely on glycolysis for energy supply. 
Different metabolite media were used here to shift the ATP production from glycolysis 
to OXPHOS. Galactose medium, containing galactose (the C-4 epimer of glucose) and 
glutamine was used to “push” OXPHOS provided by glutamine-driven oxidative 
phosphorylation (Reitzer, Wice et al. 1979).  
When HeLa cells were forced to use OXPHOS when cultured in galactose (or under 
starvation of glucose), the cytosolic translation components EIF3G and RPL7 were not 
affected in large (Figure 25A). Mitochondrial biogenesis occured after 24 hours as 
indicated by the increase of ATP5A1 and SDHA. Galactose treatment resulted in a 
starvation response and autophagy was triggered as indicated by LC3-II activation 
which is consistent with previous report (Melser, Chatelain et al. 2013). During 
prolonged starvation, LC3-II was persistently activated compared to that without 
galactose treatment. P62, also known as sequestosome 1, can bind to ubiquitinated 
proteins and LC3-II directly (Chang, Huang et al. 2001) and this interaction leads to 
degradation by autophaphy. When autophagy is ablated, p62 accumulates and forms 
p62-positive inclusion bodies (Mack and Compton 2001). The steady state levels of p62 
were relatively stable in comparison to LC3. Starvation induced autophagy is mediated 
via m TORC1 inhibition (Valente, Abou-Sleiman et al. 2004), as shown by the decrease 
of phosphorylation state of mTORC1 substrate S6K1, (S6K1Thr389).  
R e s u l t s  | 84 
 
 
Figure 25: CLUH level fluctuates with galactose treatment at different time points. (A) 
Western blot of HeLa cell lysate treated with galactose media for different times. (B) CLUH 
mRNA levels measured with qRT-PCR relative to GAPDH. Samples for A and B were from the 
same treatment. n=1 (C) CLUH level in HeLa cells in short-term galactose treatment. n=1 (D) 
CLUH transcript level measured with qRT-PCR relative to GAPDH. 
 
Intriguingly, CLUH responded to the time course treatment in an on-and-off manner, in 
both the protein and mRNA levels (Figure 25A and B). Increase of CLUH and 
mitochondrial proteins did not occur at the same time, moreover the increase of CLUH 
level seemed to precede the increase of mitochondrial proteins, ATP5A1 and SDHA 
(See CLUH level at 72 hours and 144 hours and SDHA at 96 hours and 168 hours.). 
With galactose treatment, astrin followed the same trend as CLUH, this was also true 
for SKAP, the interactor of astrin (Clark, Dodson et al. 2006) and CLUH (Désirée 
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Schatton, personal communication). Interestingly, CLUH changes overlap the changes 
seen in m TORC1 activity as indicated by S6K1Thr389.  
Briefly, in conclusion, under starvation or metabolic challenges, the mTORC1 pathway 
was inhibited in order to activate autophaphy and provide cells with nutrients, the 
protein levels of CLUH and its interactors followed the same pattern as mTORC1 while 
CLUH targets were elevated after the increase of CLUH. Importantly, CLUH was not 
upregulated in routine galactose treatment time course (i.e. compare 48 hour to time 0, 
CLUH level is decreased, this is reproducible in MEF, COS7 and HeLa cells. Data is 
not shown). Moreover, this regulation is most likely to be transcriptional since the 
mRNA level of CLUH also changed with time. However, the rise of mRNA level did 
not completely correspond to the rise of its protein level (compare the mRNA and 
protein level in 48 hours and 120 hours). Interestingly, response of CLUH, astrin, SKAP, 
mitochondrial protein, mTORC1 and LC3-II also correlated with the reseeding time of 
the cells. This complicates the interpretation of whether the fluctuation responses were 
due to the availability of nutrients, cell densities or the cell cycle.  
Nevertheless, the protein level of CLUH was reduced when treated with galactose. This 
outcome is very puzzling since CLUH binds specifically to mRNA of NEMPs and the 
steady state protein level of the targets was reduced in the absence of CLUH. These data 
support a role of CLUH in mitochondrial biogenesis. Therefore, an attempt was made to 
find the possible reasons: is RBP protein involved in translation expressed before its 
transcripts? Indeed, CLUH level increased as early as four hours with galactose 
treatment and lasted until eight hours, however at the same time point, its mRNA level 
already started to decline at 8 hours and remained even lower at 24 hours (Figure 25C 
and D). In conclusion, it is conceivable to propose that the protein level of CLUH 
increases soon after the switch from glucose to galactose. Instead of remaining at the 
increased level, CLUH level declined with prolonged galactose treatment. The reason 
for the decline remains hidden.  
Therefore, to understand the relationship between CLUH and mitochondrial biogenesis, 
we explored the question from a different angle: regardless of the changes of the protein 
level of CLUH in response to galactose, do the protein levels of CLUH target increase 
in the absence of CLUH? ATP5A1 was used here as a marker of mitochondrial 
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biogenesis (Short time course galactose treatment in MEFs was conducted in 
collaboration with Dr. David Pla-Martin). As observed in HeLa cells (Figure 25C), 
CLUH in wildtype MEF increased gradually from 4-16 hours and then decreased at 24 
hours (Figure 26A and B). However, this result was not statistically significant when 
comparing each time point to time 0. Furthermore, ATP5A1 level remained low in each 
time point in the knockout comparing to the wildtype (Figure 26A and C). This suggests 
that in the absence of CLUH, mitochondria might encounter difficulty with replenishing 
themselves with new proteins. 
MEFs were also treated with acetoacetate, a ketone body in order to switch ATP 
production from glycolysis to OXPHOS. Acetoacetate enters the TCA cycle by 
converting to acetyl-CoA by a process called ketolysis. NADH and FADH2 are then 
utilised to produce ATP. In addition to this, genes involved in ketolysis pathway were 
also found to be targets of CLUH (Table 13). These genes are HADHA, HADHB, BDH1, 
ACAT1 and OXCT1.  
In average, CLUH levels decreased after 4 and 8 hours of supply of acetoacetate 
followed by increase from 16-24 hours (Figure 26D and E). The protein levels of 
HADHA fluctuated in the wildtype MEFs: its level declined at 4 hours significantly and 
increased from 8-24 hours (Figure 26D and F). The trend of HADHA was similar to 
that of CLUH. In contrast, in Cluh knockout, HADHA level remained low at each time 
point compared to the wildtype counterpart, and was further reduced at 24 hours. This 
might be due to two possibilities: either HADHA was sensitized by CLUH, that is 
without CLUH, HADHA failed to respond. Alternatively, HADHA responded to the 
change of carbon source 20 hours later in the knockout.  
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Figure 26: CLUH levels may increase as an early response. (A, B and C) Response of CLUH 
and its target ATP5A1 to galactose treatment in wildtype and Cluh knockout MEFs. (D E and F) 
Response of CLUH and its target HADHA to acetoacetate treatment treatment in wildtype and 
Cluh knockout MEFs. Quantifications were performed using ImageJ and then standardised to 
pan-actin and time 0 of wildtype, the protein level of each point of knockout was compared to 
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4.12 CLUH protein level is reduced in PGC-1α deficient MEFs 
 
CLUH binds to a subset of NEMP mRNAs, the steady state protein level of these 
targets decreases upon CLUH deletion. It is then plausible to assume that CLUH and its 
targets could be regulated like many other mitochondrial genes under the control of 
major transcription coactivator PGC-1α in the nucleus. To testify this, protein and 
mRNA levels of CLUH/Cluh in PGC-1α knockout MEFs (kindly provided by Dr. Tina 
Wenz) were examined: in the absence of PGC-1α, both the mRNA and the protein level 
of CLUH were reduced to 0.46 and 0.51, respectively (Figure 27A and B). The extent of 
reduction of mRNA approximates the one of the protein. In line with this, CLUH could 
be upregulated when cells were treated with bezafibrate (Figure 27D). Bezafibrate is a 
pan-PPAR agonist that was shown to increase the expression of PGC-1α and is 
commonly used as a treatment for hyperlipidaemia (Tenenbaum, Motro et al. 2005; 
Bastin, Aubey et al. 2008; Srivastava, Diaz et al. 2009). 
It is worth mentioning that, when MEFs were treated with DMSO, levels of CLUH and 
its targets (ATP5A1 and OPA1) were elevated. Treatment with 550 µM of bezafibrate 
failed to induce the level of ATP5A1 or OPA1. In conclusion, bezafibrate was able to 
upregulate protein levels of CLUH additionally to that of DMSO. However, the 
upregulation of the two mitochondrial markers seemed to be mainly due to DMSO and 
bezafibrate did not give a cumulative result. 
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Figure 27: CLUH level is under the regulation of PGC-1α. (A) CLUH protein level (with 
CLUH (c-ter), also known as CLUH 05) in PGC-1α MEFs. WT and KO MEFs were collected at 
three different days and analysed by western blot. (B) Quantification of (A) relative to pan-actin. 
(C) Relative mRNA level of CLUH to β-actin. Error bar is standard deviation. * p≤0.05, ** p ≤ 
0.01. (D) Protein level of CLUH and targets of wildtype MEFs treated with either bezafibrate or 
its carrier DMSO (final concentration, 0.2 %) for different time points. The line indicates that 
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4.13 CLUH levels in mouse liver during development and aging  
 
Since CLUH level is sensitive to metabolic changes, and CLUH binds to many mRNAs 
involved in different metabolic pathways such as the TCA cycle, amino acid catabolism, 
it is plausible to postulate that either the protein or the mRNA, or both are subjected to 
regulation depending on the metabolic state of an organism. In Dictyostelium, the cluA 
mRNA increases in developing cells (Zhu, Hulen et al. 1997). The mRNA level of 
PGC-1 is elevated in mouse heart immediately after birth or 24 hours of fasting and this 
is coupled with the induction of mitochondrial genes (Lehman, Barger et al. 2000). The 
mRNA of HADHA is also induced in murine liver one day after birth (Ibdah, Paul et al. 
2001). Therefore, the level of CLUH was examined in mouse liver at embryonic stage 
18.5, two days after birth, 20 days and 20 weeks (Figure 28A and B). During 
development, there were extensive changes in the liver proteome as shown by the 
ponceau staining (Figure 28A). CLUH levels remained relatively constant until 20 
weeks of age, however the protein levels of HADHA, PCB and ATP5A1 were 
upregulated two days after birth (Figure 28B) and then decreased at 20 weeks. This 
result raised the question of whether CLUH protein level fluctuates during early 
development and hence regulating the level of its target protein, however to address this, 
one needs to examine CLUH level at different hours or one day after birth or after 
starvation. It is worth noticing that at 20 weeks, the level of CLUH as well as its targets 
declined, whether CLUH is directly involved in this regulation is unknown. This 
observation has motivated me to examine the protein levels of the targets in the liver 
from Cluh knockout mice (Figure 28C and D). Since Cluh knockout mice died soon 
after birth, we could only obtain the organ at E18.5 by C-section. However, the protein 
levels of PCB (about 23 % remaining) and HADHA (about 21 % remaining) were both 
significantly decreased before birth.  
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Figure 28: CLUH targets are subjected to developmental changes. (A) Ponceau staining of 
membrane in (B) showing the differences of total proteomes at different developmental stage of 
murine liver. (B) Western blot with CLUH targets decorated. (C and D) In the absence of 
CLUH in liver, CLUH targets level were decreased significantly. **** p ≤0.0001,** p≤0.001. 
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4.14 Identification of the function of CLUH protein domains  
 
Despite the conservation of CLUH across evolution (introduction Figure 7), little is 
known regarding the function of its domains. As mentioned earlier, human CLUH is 
comprised of 1347 amino acids. Five protein domains can be identified by EMBL-EBI 
combined with NCBI Conserved Domains. CLU_N domain is also known as TIF31-like, 
eIF_ p135 domain is also known as CLU-central. In order to study the molecular 
function of CLUH, we established inducible HEK 293T cell lines that overexpress 
different CLUH deletion constructs lacking one or more identified domains (Figure 
29A). All of the constructs were tagged with FLAG at their C-termini. The preliminary 
data showed that, after 16 hours of induction, the proteins can be overexpressed and this 
did not lead to obvious cell death (based on observation) in all clones for each construct. 
The respective proteins could be extracted with RIPA buffer (Figure 29B-E) however, 
the amount of the protein remaining in cell pellet after lysis was unknown, therefore it is 
not sure if all proteins could be solubilised by RIPA. All non-induced constructs were 
leaky; this could be seen in the non-induced lanes. The tagged proteins migrated 
according to their expected size: Δ1021-1347 at 114 kDa and Δ1-352 at 111 kDa, 
however Δ801-1347 (expected: 89 kDa) and Δ1-615 (expected: 81kDa), somehow 
shows a bigger than expected size. One clone of each constructs was chosen for further 
analysis and annotated later as “c1” or “c2”. 
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Figure 29: Generation of inducible HEK 293T cell lines with deletion of different domains 
of CLUH. (A) Illustration of the constructs. (B-E) Western blot with anti-FLAG antibody to 
test the expression level of the corresponding proteins. Δ1021-1347, expected size: 114 kDa; 
Δ801-1347, expected size: 89 kDa Δ1-352, expected size: 111 kDa; and Δ1-615 expected size: 
81kDa.  
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To identify the RNA binding domains of CLUH, CLIP experiments using different 
deletion constructs were conducted. After overexpression, the HEK 293T cells were 
exposed to 400 mJ (same as for CLUH-FALG and FLAG) of UV irradiation at 254 nm 
and CLIP was conducted similarly as before. One tenth of the elution before end-
labeling was reserved for western blot analysis. The autoradiogram did not reveal if any 
of the constructs were able to bind to RNA, Δ1-352 might be able to bind but this need 
to be validated with less RNase I treatment to see if the band smears up. However 
considering its presence in Δ801-1347, the identity of this band is questionable. The 
positive control CLUH-FLAG worked (as indicated by the arrowhead in long exposure), 
though with considerable amount of background RNA signals (Figure 30B). All 
constructs could be immunoprecipitated (Figure 30C) but in different quantities. Since 
the starting amount of proteins were not known here, it was not possible to conclude 
whether the immunoprecipitation efficiency was low for the other constructs or if these 
constructs were expressed at a lower level. 
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Figure 30 : Preliminary CLIP experiment to test the RNA binding activity of the 
constructs of CLUH. (A) Illustration of the CLUH constructs. (B) CLIP with anti-FLAG 
antibody of each constructs. The dried gel was exposed for short (2 hours) and long (5 hours) 
time. Arrowheads indicate the approximate locations of the expected RNA-Protein complexes. 
(C) Western blot of (B) indicating the efficiency of immuoprecipitation.  
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To examine the cell morphology after overexpression of different CLUH constructs and 
to ensure that CLUH overexpression is not lethal or harmful to the cells, 
immunocytochemistry was applied to examine the subcellular localisation of CLUH, 
and the general morphology of mitochondria and cells (Figure 31). First of all, the 
morphology of the full length CLUH was assessed. A small portion of CLUH-FLAG 
cells was able to express the protein without induction (Figure 31G). When overly 
expressed, CLUH was present in the cytosol as puncta/granular structures without 
forming any observable aggregates (Figure 31G and J). However, some cells displayed 
many vacuole structures devoid of CLUH, the identity of this structure is unknown 
(Figure 31J, white box). Clustered mitochondria were observed in both empty FLAG 
and CLUH-FLAG overexpressed cells indicating that mitochodnrial clustering was 
independent of CLUH overexpression (see white arrows in Figure 31C, F, I and L). 
However, mitochondria in FLAG cell line without induction revealed more elongated 
morphology than the other three conditions (compare B to E, H and K) 
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Figure 31: Morphology of CLUH, mitochondria and HEK 293T upon CLUH overexpr (A-
L) After 16 hours of induction, cells were fixed and stained to visualise CLUH (green) and 
mitochondria (red). Blue staining is DAPI for nuclei. Whitte box area highlights the cytosolic 
space that is devoid of CLUH. Yellow box shows the enlarged image. Arrows indicate cells 
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In comparison, no overt abnormality of mitochondria could be observed in the CLUH 
deletion constructs compared to their non-induced controls, such as mitochondrial 
clustering, fission and fusion problems. Different CLUH constructs displayed cytosolic 
staining of CLUH with punctate structures (Figure 32A, D, G and J). Δ801-1347c1 
puncta appeared to be more granular compared to full-length CLUH construct. The 
vacuole structures were present in the cytosol of Δ1-352c1 and Δ1-615c1, but were not 
evident in Δ1021-1347c2 and Δ801-1347c1. 
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Figure 32: Overexpression CLUH deletion constructs. Cells were induced with 1µg/ml of 
tetracycline for 16 hours. (A, D, G and J) are the overexpressed proteins stained with anti-
FLAG antibody. (B, E, H and K) are mitochondria stained with TOM20. (C, F, I and L) are the 
merged images between Anti-FLAG, TOM20 and DAPI (for nuclei staining). Bar: 20 µM for 
A-L, 120 µM for the zoomed images. Images were taken with Apotome with one Z- stack. 
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5.1 Elucidation of the molecular function of CLUH unravels the cause of Clu 
mutant phenotypes. 
Clu is well conserved throughout evolution and yet not much is known about its 
molecular function. In this study, we discovered that CLUH is coregulated with two 
gene clusters: one included genes involved in RNP complex biogenesis, ribosome 
biogenesis, and the other included mitochondrial genes involved in electron transport 
chain, oxidative phosphorylation, TCA cycle, and generation of small metabolite and 
energy (Figure 10). Next, we identified that CLUH is a genuine RNA binding protein 
(Gao, Schatton et al. 2014). This finding is in agreement with a systematic study in 
HeLa cells to identify mammalian mRNA binding proteins, which proposed CLUH 
(KIAA0664) as a candidate mRNA binding protein (Castello, Fischer et al. 2012). 
Among the RNAs bound by CLUH, we found a significant enrichment of mRNAs 
encoding for mitochondrial proteins. Canonical pathways analysis of these genes 
indicated clusters of genes involved in various metabolic pathways: branched-chain 
amino acid degradation, TCA cycle and oxidative phosphorylation (Table 13). However, 
our analysis has been so far restricted to mRNAs enriched for more than five times with 
a P value of less than 0.01. The steady state protein levels of CLUH targets were 
reduced (Figure 19A, see discussion below) and this was likely to be caused by specific 
regulation of translation of these transcripts (Figure 19B, 21 and 22) in the absence of 
CLUH.  
Our findings help to explain some of the phenotypes observed in Clu mutants. 
Reduction of mitochondrial protein levels, aconitase activity and ATP in Drosophila 
mutant (Cox and Spradling 2009; Sen, Damm et al. 2013) could be direct results from 
failure in translation of these targets. This is strongly supported by our data wherein 
many enzymes participating directly in TCA cycle are targets of CLUH, including 
aconitase 2 (ACO2). In fact, only three enzymatic steps in TCA cycle are devoid of 
CLUH targets: conversions to succinate, α-ketoglutarate and citrate. Therefore, it is 
reasonable to speculate that NADH and FADH2 levels also decline as a result of an 
insufficient TCA cycle. Subsequently, ATP production by OXPHOS could also be 
affected. Furthermore, our data hinted that CLUH is engaged in coordinating 
mitochondrial adaptation to the change of metabolism in the cells, because of the 
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involvement of CLUH targets in pathways interconverting different metabolites 
(especially amino acids) within TCA cycle. 
The molecular function of Clu was long speculated to be involved in the transport of 
mitochondria. The reason for this was mainly due to the well-known mitochondrial 
clustering phenotype in the absence of Clu in all organisms investigated by the other 
research groups. The hypothesis was also supported by other observations: (1) 
Disruption of microtubules or actin did not lead to clustering of already positioned 
mitochondria in Dictyostelium. (2) Microtubule network was intact in Clu mutant. (3) 
Some Clu particles were found to be close to mitochondria. (4) Some Clu particles were 
also found to be close to microtubules. (5) Mitochondria accumulated at the microtubule 
plus end in fly mutant.  
However, there is no direct evidence to support this hypothesis. A thorough study of the 
Arabidopsis mitochondrial cluster shed light on whether Clu was the linker between 
mitochondria and the cytoskeleton. Transport of mitochondria and mitochondrial 
clusters were intact along the actin filaments. The formation of clusters is likely due to 
prolonged association between the mitochondria (El Zawily, Schwarzlander et al. 2014). 
The authors proposed that mitochondrial clustering might be a secondary response to 
cell stress.  
Our finding of the molecular function of Clu partially agree with El Zawily et al. that 
mitochondrial clustering phenotype may be secondary in Clu mutants. Moreover, Clu 
that associates with microtubules could be transporting mRNP (Figure 33). There are 
three possible causes for the mitochondrial clustering phenotype. First of all, lack of 
ATP due to reduced production of mitochondrial proteins leads to mitochondrial 
clustering. This is because the limited amount of energy is being used for primary 
cellular functions such as nuclear replication, protein synthesis and cell proliferation. 
Therefore, less ATP is available to transport mitochondria. Secondly, if CLUH is 
important for the transport of the mRNP to mitochondria, mitochondria might cluster to 
the region where mRNAs are present in the absence of CLUH. In fly Clu mutant, 
mitochondria are still transported to Balbiani body (Cox and Spradling 2009). However, 
translation inhibition with 30 min treatment of cycloheximide did not cause 
mitochondria to cluster in HeLa cells (data not shown), which argues against this 
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hypothesis. Nevertheless, it is likely that the treatment time was not long enough for 
mitochondria to accumulate. Lastly, the clustering phenotype could be due to longer 
association of mitochondria in order to facilitate content exchange to overcome limited 
protein supply as proposed by El Zawily and colleagues. 
Other two very interesting CLUH targets are SPAG5 and PINK1 (Table 11). SPAG5 
encodes for astrin, a cytosolic protein. This protein is a mitotic spindle associated 
protein and regulates mitotic progression (Chang, Huang et al. 2001; Mack and 
Compton 2001). Recently Thedieck and colleagues discovered that astrin is a negative 
regulator of mTORC1 in cellular stress response (Thedieck, Holzwarth et al. 2013). Our 
proteomics study in HeLa cells show interaction of CLUH with astrin (Désirée Schatton, 
personal communication), moreover the steady state level of CLUH and astrin are 
tightly coupled. Therefore CLUH associates with both the mRNA and the protein of 
astrin and regulates it through a yet to be determined function. The reason behind such 
level of regulation remains unsolved. However, it is reasonable to speculate that by 
modulating astrin, CLUH participates in the regulation of mTORC1 pathway and hence 
connecting mTORC1 to mitochondria in the respect of metabolic alterations.  
PINK1 (Pten-induced kinase 1) is a mitochondrial Ser/Thr kinase (Valente, Abou-
Sleiman et al. 2004) that genetically interacts with Parkin (E3 ubiquitin ligase) in 
Drosophila for maintenance of mitochondrial function upon stress via mitophagy (Clark, 
Dodson et al. 2006; Narendra, Jin et al. 2010). PINK1 accumulates on the mitochondrial 
OM when mitochondria are dysfunctional and recruits Parkin to evoke mitophagy. 
Mutations in both genes can cause Parkinson’s disease (Kitada, Asakawa et al. 1998; 
Valente, Bentivoglio et al. 2001). Interestingly, Drosophila Clueless and park mutants 
share many similar features and these two genes also interact genetically and may 
function in a similar pathway (Cox and Spradling 2009). More strikingly, however, 
Gehrke and colleagues recently discovered that PINK1 is an RNA binding protein. It 
associates with OXPHOS related mRNAs and translation initiation factors. 
PINK1/Parkin is involved in the translation of the localised mRNAs by replacing the 
translation repressors (Gehrke, Wu et al. 2015). Our finding of PINK1 being a target of 
CLUH provides a possible explanation for the genetic interaction between Clu and Park: 
Clu could regulate the protein level of PINK1, without Clu, PINK1 is reduced and gives 
rise to defective mitophagy as well as reduced translation initiation of some of the 
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OXPHOS mRNAs bound by PINK1. Whether CLUH is directly involved in 
PINK1/Parkin mediated RNA translation pathway awaits to be solved. However PINK1 
under normal physiological conditions is constantly degraded by mitochondrial 
proteases as well as the proteosome (Jin, Lazarou et al. 2010; Greene, Grenier et al. 
2012; Yamano and Youle 2013) whereas the translation of mitochondrial proteins needs 
to be maintained under physiological conditions. Therefore, it is difficult to comprehend 
how PINK1 might play a role to constantly facilitate localised translation of these 
mRNAs.   
Identification of CLUH as an mRNA binding protein also explains the association of 
Clu1 with translation initiation eIF3 complex (Vornlocher, Hanachi et al. 1999). First of 
all, in line with the observation from Vornlocher et al., we did not observe any 
alteration of global translation in the absence of CLUH (Figure 21) and the main portion 
of CLUH did not peak with any of the translation machineries (Figure 24C). However, 
it is possible that CLUH interacts with the translation machineries only when translating 
the target mRNAs. It is also possible that this interaction is transient and difficult to 
catch, for example, CLUH might play a role in transferring translationally repressed 
mRNP complex to translationally activated mRNPs. 
There are still several questions that need to be addressed in understanding the 
molecular function of CLUH. Primarily, since the function of each CLUH domain is 
unknown, evaluation of each protein domain and their post-translational modification 
will provide important information on the activity of CLUH and its regulation. 
Furthermore, study of CLUH domains can expand our knowledge on mRNA binding 
proteins and help to identify similar proteins. In addition, identifying the RNA signature 
recognised by CLUH also serve the same purpose.  
Next, because CLUH disperses in the cytosol (Figure 23), it is not known at which stage 
during an mRNA’s life does CLUH bind to the target mRNAs. Since CLUH is not 
found in the nucleus, it is likely that it binds to its mRNAs after the nuclear export of 
the mRNP. Because some CLUH associates with microtubules (Cox and Spradling 
2009; Gao, Schatton et al. 2014), this points to a possible role of CLUH in mRNP 
transport/localisation. Based on the observations that the protein levels of CLUH targets 
are reduced in Clu mutant possibly due to specific translational regulation (Figure 19 21 
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and 22), it is conceivable that CLUH is a positive and specific regulator of translation. 
However, whether CLUH regulates mRNA stability or translation directly or acts in 
both processes are so far not very clear.  
The last question with respect to the molecular function of CLUH would be the 
elucidation of the function of CLUH that associates with mitochondria (Figure 24) (Cox 
and Spradling 2009; Gao, Schatton et al. 2014). Two possibilities could be postulated 
here: either CLUH anchors mRNPs on the surface of mitochondria or CLUH transiently 
associates with mitochondria and transfer the mRNP to a receptor or a protein present 
on mitochondria. To address these questions, it is important to understand if all CLUH 
molecules bind to RNA or only the ones associated with microtubules and mitochondria 
contain RNA. This can be achieved by double staining of CLUH and RNA. In this study, 
mRNAs bound by CLUH were analysed regardless of their subcellular location, 
however it is conceivable that the mRNP components containing CLUH vary 
considerably depending on its subcellular localisation. Therefore, to facilitate the 
understanding of CLUH function, it is pivotal to study its interacting partners in 
different subcellular location. This can be achieved by immunoprecipitating CLUH and 
its interactors after crude cell fractionation. 
In a genome wide analysis of mRNAs that are targeted to yeast mitochondria, the 
NEMP mRNAs can be divided into two pools: proteins with eukaryotic origin are 
translated in the cytosolic polysomes whereas proteins with bacterial origin are 
translated on the mitochondrial bound polysomes (Marc, Margeot et al. 2002). The 
mitochondrial bound mRNAs can be further divided to class I mRNAs, which contain 
3’-UTR Puf3p binding motif, and class II mRNA that does not contain Puf3p binding 
site (Saint-Georges, Garcia et al. 2008). Similarly, it would be interesting to compare 
the mRNAs bound to mitochondria in Cluh knockout MEFs to conclude if CLUH is 
important for mRNA targeting/anchorage to mitochondria and identify the mislocalised 
mRNAs if there is any.  
Considering the conservation of Clu proteins, it would be extremely informative to 
investigate if Clu binds to similar mRNAs in the other organisms. It is possible that Clu 
is an RNA binding protein in the other organisms due to its high conservation. However, 
whether Clu binds to a similar set of mRNA is doubtful. A good example is the PUF 
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proteins: apart from yeast Puf3p, none of PUF proteins in the other organisms are found 
to associate with the NEMP mRNAs of mitochondrial proteins in spite of conservation 
of their RNA binding domain and the RNA motif recognised by PUFs (Quenault, 
Lithgow et al. 2011). However, since the absence of Clu leads to mitochondrial 
clustering in all organisms tested, if the clustering phenotype is a secondary response to 
reduction of certain mitochondrial proteins, it is possible that Clu associates with a 
similar set of mRNAs encoding NEMPs. 
 
Figure 33: Schematics of possible molecular function of CLUH in respect to its 
RNA binding activity.  
 
5.2 Identification of the molecular function of CLUH could be a support for co-
translational import  
 
Identification of the molecular function of CLUH inevitably raises the discussion over 
co-translational versus post-translational import. The main dispute is focused on 
whether mRNAs or proteins are being targeted to mitochondria (see introduction). 
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However if post-translational import were the only model for protein targeting to 
mitochondria, then the existence of mRNA sorting and targeting to mitochondria would 
be redundant. CLUH, on the other hand is a member of mRNA targeting machinery due 
to its RNA binding activity and possible localisation to mitochondria (see discussion 
about the localisation below). Nevertheless, CLUH might not be the only protein 
conducting this role; other RBPs might have a similar function and binds to another 
subset of mRNAs.  
So far, there is no strong evidence that CLUH is localised to mitochondrial outer 
membrane. Immunocytochemistry under high glucose and galactose condition does not 
reveal any observable difference in CLUH/mitochondria colocalisation (Figure 23). 
Presence of CLUH in mitochondrial fraction could be a result of contamination from the 
ER (Figure 24A). The colocalisation between CLUH and mitochondria was observed 
upon extraction of the the soluble cytosolic CLUH with detergent (Gao, Schatton et al. 
2014). However, it is not known if the observation was caused due to the the extraction 
(Gao, Schatton et al. 2014). On the other hand, researchers from other labs observed that 
Drosophila clu is in close proximity to mitochondria (Cox and Spradling 2009). To 
better understand the localisation of Clu to mitochondria, EM coupled with 
immunogold labeling of CLUH can be used. It is also possible that like PINK1 and 
Puf3p, CLUH interacts with one of the TOM receptors such as TOM20 and TOM70 or 
the translocase TOM40. Undoubtedly, if CLUH resides on mitochondria together with 
mRNAs, then mRNA targeting to mitochondria exists in mammals as previously shown 
(Matsumoto, Uchiumi et al. 2012; Gehrke, Wu et al. 2015) and this would provide a 
strong support for co-translational import of mitochondrial proteins.  
 
5.3 CLUH affects the levels of protein encoded by target mRNAs  
 
As mentioned before, the steady state protein levels of CLUH targets were reduced in 
Clu mutants. The steady state transcripts level of CLUH targets remains unchanged at 
large when CLUH is deleted or depleted (Figure 19B) and (Gao, Schatton et al. 2014). 
However, Atp5a1 transcript level is consistently reduced. Nevertheless, the reduction of 
steady state protein level is more than the steady state level of its transcripts (Figure 19 
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and 21). In line with this observation, preliminary data in cluh knockout MEFs indicated 
a failure of translation for target SDHA, ATP5A1 and OGDH but not cytosolic protein 
GAPDH and the mitochondrial OM protein TOM20 (Figure 21 and 22). However, we 
have several limitations to conclude that CLUH controls the translation of its target 
mRNA directly. First of all, there is no data so far showing the stability of the target 
mRNAs in the absence of CLUH. The steady state mRNA level is an outcome of 
transcription and degradation. Increased mRNA degradation can also lead to translation 
reduction of the respective proteins. Furthermore, mRNA degradation could induce the 
compensatory increase in nuclear transcriptions which masks the unstability of the 
mRNA and displays an unchanged level in the transcripts. The second drawback lies 
within the system due to compensatory mechanisms: it is difficult to distinguish direct 
and indirect responses in mRNA stability and translation.  
For some target mRNAs, we did not observe a decrease in their protein products. For 
example, the steady state protein level of SDHA was unchanged in Cluh knockout 
MEFs. It is conceivable that the immortalised MEFs adapted to the culturing conditions, 
for example some of the target proteins could have adapted to a slower protein turnover 
rate or the transcription or translation machineries compensated for the loss of CLUH. 
The steady state level of proteins is also the result of the existing and the newly 
synthesised proteins. Therefore, proteins with a slow turnover rate and a reduced 
translation might not be readily detected without looking into the two subspecies 
separately. In fact, reduction of newly synthesized SDHA was observed while the 
steady state level of SDHA remains unchanged (Figure 22).  
The effect of CLUH over its targets cannot be simply explored by modulating CLUH 
protein levels. This is based on two observations: (1) as aforementioned, in the absence 
of CLUH, steady state level of SDHA is not affected in MEFs. (2) CLUH 
overexpression in HEK 293T cells results in increased, decreased or unchanged protein 
levels of its targets (Figure 20). The above observations raise the possibility that CLUH 
does not regulate its targets mRNA in the same manner. Furthermore, overexpressed 
CLUH could overstabilise its targets and inhibit the subsequent translation. Global 
analysis of translation of CLUH targets should be conducted in Cluh knockout as wells 
as overexpression to identify targets whose translation is directly influenced by the level 
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of CLUH. Caution should be taken for possible compensatory effects in translation in 
the absence of CLUH.   
If CLUH is indeed involved in the translation of its targets, initiation of translation of 
the targets mRNAs might require special signals and thus without it, translation cannot 
be initiated and results in unchanged protein levels. Signals can be in the forms of 
change of interactors or post-translational modification of CLUH. Moreover, this 
upstream modification can be a result of cellular alteration of, for example, a metabolic 
shift upon stress, development growth and aging. In other word, under physiological 
conditions, it is the “activation” of CLUH function rather quantitative elevation that 
drives the translation of some of its target mRNAs.   
Another interesting observation is that up or down regulation of CLUH can both lead to 
reduction of HADHA. This indicates that CLUH levels are closely affecting the steady 
state protein level of HADHA which implies the importance of maintaining the 
homeostatic state of CLUH for regulating its targets. In conclusion, CLUH is a positive 
translation regulator, because its deletion never led to increase in the steady state target 
protein levels. CLUH could stabilise mRNAs and promote translation upon receiving 
signals or bring mRNA to the right place for translation. On the other hand, CLUH 
overexpression data implicates complex interactions with other factors to regulate 
expression of target mRNA. 
 
5.4 Regulation of CLUH  
 
5.4.1 Effect of galactose treatment on CLUH  
 
CLUH affects the expression of its target mRNAs and RNA binding proteins have been 
shown to be coregulated with their target genes (Jiang, Xu et al. 2014). Therefore I 
anticipated that CLUH expression increases when mitochondrial biogenesis occur. 
Consequently, I used galactose treatment to induce mitochondrial biogenesis in order to 
examine the response of CLUH. In galactose media, glutamine is the main carbon 
source for ATP production. After entering mitochondria, glutamine is converted to 
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glutamate and α-ketoglutarate, which joins the TCA cycle. Intriguingly, CLUH 
decreases after 24 hours and longer galactose treatment (Figure 25A and C). This 
conflicts with the hypothesis that CLUH is involved in mitochondrial biogenesis. 
However, by chance when I treated MEFs for 16 hours with galactose as a positive 
control, I observed that CLUH level was increased. Inspired by this, I cultured HeLa 
cells in galactose for a shorter time and observed that CLUH levels increased after 4-8 
hours of treatment. Similar observation was made also in MEFs (Figure 26A and B). 
Therefore, I propose that CLUH is important very early on when metabolic switch 
occurs. This hypothesis is supported by examining the CLUH target ATP5A1. ATP5A1 
failed to be expressed to the wildtype level in the absence of CLUH after short galactose 
treatment (Figure 26A and C).  
I then attempted to investigate if CLUH expression is under the control of the master 
transcriptional coactivator PGC-1α, an important indicator for mitochondrial biogenesis. 
In favor of the hypothesis, about 50% of Cluh was not expressed in the absence of PGC-
1α (Figure 27A, B and C). Moreover, CLUH level could be induced by the pan-PPAR 
agonist bezafibrate (Figure 27D). In line with the above observations, Nsiah-Sefaa et al. 
demonstrated that Cluh mRNA level increased with PGC-1α overexpression in mouse 
myotubes as well as treatment with AICAR (activator of AMPK). Furthermore they 
postulated through bioinformatics studies that PGC-1α co-activates ERRα, and binds to 
the promoter of Cluh (Nsiah-Sefaa, Brown et al. 2014). Together, the above 
observations provide strong indications that CLUH is involved in mitochondrial 
biogenesis. This is consistent with our observation that CLUH is a positive regulator of 
translation of its target mRNA and coregulated with some of its target genes (Figure 10). 
The coregulation might be under the control of PGC-1α.  
However, it is still enigmatic why levels of CLUH are reduced after long galactose 
treatment. It is plausible that CLUH needs to be translated first and then facilitate the 
translation of its targets. However, prolonged expression of CLUH might inhibit 
expression of its targets or the other proteins. The evidence to support this is the 
reduction of HADHA after CLUH overexpression (Figure 20). Another possibility is 
that CLUH is involved in another pathway and needs to be regulated accordingly. 
CLUH might be involved in the mTORC1 pathway for nutrient related response. CLUH 
level changed through different time points and correlated with the level of 
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phosphorylation of S6K1 at Thr389 (this site is directly phosphorylated by mTORC1/ 
raptor) and activation of LC3-II (indicator of autophagy activation, downstream of 
mTORC1). Another possibility is that CLUH could be affected by cell cycle. This is 
supported by the observation that CLUH level fluctuated and correlated with the 
reseeding time and the mitotic marker astrin and SKAP. 
The protein levels of astrin and SKAP are known to be mitotically upregulated to 
facilitate chromosome alignment (Fang, Seki et al. 2009; Dunsch, Linnane et al. 2011; 
Thedieck, Holzwarth et al. 2013). However, astrin can interact with SKAP in interphase 
and in asynchronised cells. Both proteins interact with CLUH in asynchronised cells 
(Désirée Schatton, personal communication). S6K1 phosphorylation can be affected by 
multiple cells signaling pathways: Ser-411 phosphorylation is mediated by Cdk5 not 
mTOR/raptor. It is a prerequisite for subsequent phosphorylation of Thr389. Therefore, 
phosphorylation of S6K1 is also subjected to cell cycle control through G1 to S phase 
(Hou, He et al. 2007). In mitotic cells, Cdk1 phosphorylates multiple sites of S6K1, but 
correlates with reduced level of Thr389 phosphorylation (Shah, Ghosh et al. 2003). 
Therefore, in long-term galacotose experiments, if the cyclic response of CLUH is due 
to cell cycle, then there is a conflict between cell cycle makers. Mitotic marker SKAP 
and astrin activations cannot occur at the same time as Thr389 phosphorylation of S6K1. 
Fluctuation of CLUH in regard to the cell cycles seems to be unlikely.  
On the other hand, nutrient availability in combination with cell density might be a 
plausible cause for the change of CLUH. The level of S6K1 activation is in agreement 
with the availability of nutrients. As mentioned before, astrin and SKAP form 
complexes in interphase with a yet unknown function. Therefore, it is difficult to 
interpret its fluctuation upon galactose treatment. However, in our lab we observed that 
the protein levels of CLUH, astrin and SKAP are closely coupled. Astrin and SKAP are 
always influenced by the level of CLUH. Therefore, I propose that astrin and SKAP 
fluctuated because of the change of CLUH in galactose treatment. However, whether 
CLUH fluctuated with nutrients availability/cell density regardless of galactose needs to 
be investigated further. Nevertheless, it is difficult to look into nutrients availability/cell 
density and cell cycle independently since they are interconnected: the nutrient sensing 
mTORC1 controls cell growth and proliferation while mTORC1 inhibition by 
rapamycin arrests cell cycle at G1(Heitman, Movva et al. 1991).  
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5.4.2 CLUH level during acetoacetate 
 
Acetoacetate is another media routinely used to induce mitochondrial biogenesis. In 
contrast to glutamine, acetoacetate converge to the TCA cycle by conversion to acetyl-
CoA via acetoacetyl-CoA. Since both galactose and acetoacetate media enhance 
OXPHOS by providing excessive substrate to the TCA cycle, the response of CLUH 
was assumed to be very similar between these two treatments. Even though galactose 
and acetoacetate both induce mitochondrial biogenesis by feeding the TCA cycle, 
CLUH responded very differently to each of them. Four hours after the treatment with 
acwetoacetate, CLUH was reduced, however its level increased from 16-24 hours. This 
is in contrast to an increase of CLUH from 4-16 hours in galactose and a reduction after 
24 hours. Its target HADHA followed the same trend as CLUH upon treatment with 
acetoacetate. HADHA is an enzyme involved in the last three steps of branched-chain 
fatty acid beta-oxidation and participates in branched-chain amino acid catabolism as 
well as ketolysis. CLUH should be very similar between galactose treatment and 
acetoacetate treatment. CLUH target ACAT1 is directly involved in ketolysis to convert 
acetoacetate-CoA to two molecules of acetyl-CoA. Therefore, I suspect the difference in 
CLUH could be a result of different nutrient response mediated by other cellular 
signaling pathways. One report observed decrease mTOR1 activity in rat liver and 
hippocampus when fed with ketogenic diet (McDaniel, Rensing et al. 2011). As seen in 
galactose treatment, CLUH level correlated well with activation of mTOR1. However, it 
might be possible that mTORC1 modulates CLUH level in the early hour of 
acetoacetate treatment. 
Change in the steady state level of HADHA could be a consequence of metabolic shifts. 
When acetoacetate was first added to cells, the source of acetyl-CoA is shifted from 
pyruvate to ketone bodies. After persistent supply, excess acetyl-CoA is converted to 
fatty acids. Untill this step HADHA is not required and resulted in a reduction in protein 
level. From 8 to 24 hours, levels of HADHA increased and this might due be to the 
upregulated pathways in fatty acids or branched-chain amino acids catabolism.  
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5.4.3 CLUHs level during different life stages in mouse liver  
 
Metabolic switch appears to influence at least the steady state protein level of CLUH 
(Figure 25 and 26). Moreover, many multicellular organisms experience metabolic 
switch during their development. Fly Clu larval mutant that mainly utilise glycolysis for 
energy supply do not show any defect in ATP production, aconitase activity and growth 
defect compared to the wildtype. However the mutant adult displayed all defects of the 
aforementioned phenotypes. Moreover the newly formed adult mutants have problems 
in utilising the larval fat body. Therefore, I hypothesised that CLUH plays a role in 
metabolic switch in vivo. 
During mammalian embryogenesis and fetal development, glycolysis is the main source 
for energy supply (Cuezva, Ostronoff et al. 1997). As soon as one hour after birth, rat 
neonatal liver mitochondrial biogenesis occurs as a result of cytosolic translation 
(Valcarce, Navarrete et al. 1988). Concurrently, mRNAs of nuclear encoded 
mitochondrial proteins accumulate compared to adults as a result of stabilization of the 
transcripts (Izquierdo, Ricart et al. 1995). One of the transcripts ATP5B is even 
localised close to mitochondria (Egea, Izquierdo et al. 1997) and preferentially 
translated one hour after birth (Luis, Izquierdo et al. 1993). 
To test if CLUH protein level is subjected to metabolic switch, I collected murine livers 
from different ages and examined the steady state level of CLUH and its targets. 
HADHA, PCB and ATP5A1 increased at D2, which are indications of mitochondrial 
biogenesis due to metabolic switch. However, CLUH protein level remains unchanged 
during this process. This paradoxical observation might be due to three possibilities. If 
CLUH participates in the translation of its target within one hour after birth, then (1) 
CLUH might be translated rapidly within this time before the translation of its targets 
(similar to the situation proposed for galactose treatment). Therefore, in order to see the 
difference of CLUH, one needs to examine its level in one hour or less after delivery. (2) 
CLUH protein is translated in the cytosol before birth and simply waiting for signals to 
be functional. This could be the availability of oxygen in the animal´s system after birth 
or interruption of the umbilical supply of certain nutrients. (3) CLUH function is 
upregulated by regulating its activity not its quantity. The first two possibilities involve 
elevation of CLUH whereas the third requires participation of post-translational 
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modification or co-activator. In reality, all three hypotheses are plausible however 
considering the fluctuation of CLUH observed with galactose treatment, the first two 
hypotheses are favored.    
CLUH is already important for the expression of its target at the basal level (E18.5, 
Figure 28 C and D). Therefore, when translation of CLUH targets fail after birth, severe 
defects can occur from multifaceted pathways. In fact, from function and diseases 
pathways analysis (Table 14), the top five pathways are involved in mitochondrial 
disorders, inborn error of amino acids metabolism, organic aciduria, aciduria and fatty 
acid oxidation disorder. Hence, short life expectancy in Drosophila could mainly be due 
to defect in metabolic imbalance. In fact, fat bodies were found to accumulate in adult 
fly mutants. The metabolic failure of the mutants could be tested by examining the 
metabolites of adult flies and the mutant might be rescued by feeding with special food 
supplement.   
5.5 Conclusions 
 
In conclusion, in the course of this study, I demonstrated the unexpected role of CLUH 
as an mRNA binding protein. It binds to a subset of mRNAs encoding NEMPs. A 
majority of CLUH does not associate with the 40S, 60S, 80S or polysomes even though 
a small portion of CLUH forms higher molecular complexes. Deletion or depletion of 
CLUH does not lead to obvious alteration of the general translation machinery. In the 
absence of CLUH, the protein levels of majority of its targets decrease and this is very 
likely due to failure in translating these targets specifically. CLUH levels are affected by 
different nutrients and the regulation of CLUH with respect to the nutrients can be 
important when metabolic switch is required in vivo.  
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Zusammenfassung 
Das mitochondriale Proteom besteht sowohl aus mitochondrial- als auch aus nuklear-
kodierten Proteinen. Bei Schwankungen in der Nährstoffverfügbarkeit und unter 
Stresszuständen ist die Restrukturierung des mitochondrialen Proteoms nötig. Um 
diesen Prozess zu ermöglichen, muss die Proteinexpression des nuklearen und des 
mitochondrialen Genomes genauestens koordiniert werden. Es sind zusätzliche 
Faktoren vorhanden, die diese Koordination bestimmen. Diese Faktoren haben 
verschiedene Funktionen von Energieregualtion bis hin zu Translation von spezifischen 
nukelar-kodierten mitochondrialen Proteinen.  
Clu ist ein hoch-konserviertes cytosolisches Protein, jedoch ist seine molekulare 
Funktion bis bisher unerforscht. In Drosophila wurde eine kleine Menge Clu an der 
Außenseite von Mitochondrien beobachtet. Clu-Mutanten in multi-zellulären 
Organismen zeigen einen Wachstumsdefekt, den Mangel sich an Stress anzupassen und 
frühzeitigen Tod. In einzelligen Organismen können diese Phänotypen jedoch nicht 
beobachtet werden. Nichtsdestotrotz, alle Clu-Mutanten besitzen akkumulierte 
Mitochondrien, dies eröffnet Raum zu spekulieren, dass die Funktion von CLUH eng 
mit Mitochondrien verwoben ist.   
In dieser Studie haben wir Gene analysiert, die sowohl mit dem humanen als auch mit 
dem murinen CLUH/Cluh-Gen coreguliert sind. Dabei konnten wir zwei Haupt-
Gencluster identifizieren: nuklear-kodierte mitochondriale Proteine und Gene, die in der 
cytosolischen Translation involviert sind. Danach haben wir mit Hilfe von Crosslinking 
Immunoprezipitations-Experimenten (CLIP) herausgefunden, dass das humane CLUH 
ein mRNA-Bindeprotein ist. Bei dem Vergleich der mRNAs, die mit CLUH 
angereichert wurden mit denen, die mit dem Kontroll-IgG angereichert wurden, konnten 
wir feststellen, dass CLUH spezifisch an die mRNA von nuklear-kodierten 
mitochondrialen Proteinen (NEMPs) bindet.   
Unter den mRNAs, die von CLUH gebunden werden, haben wir eine Anreicherung von 
Genen festgestellt, die in dem Abbau von verzeigtkettigen Aminosäuren, 
mitochondrialer Dysfunktion, dem TCA-Zyklus, oxidativer Phosphorylierung und der 
α-Oxidation von Fettsäuren involviert sind. Des Weiteren konnten wir zeigen, dass 
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CLUH ein positiver Translations-Regulator seiner Ziel-mRNAs ist, da in Abwesenheit 
von CLUH die Translation der Ziel-mRNAs vermindert zu sein scheint. Jedoch ist die 
allgemeine Translation der Zelle nicht betroffen. Des Weiteren haben wir 
herausgefunden, dass das CLUH-Level in PGC-1α-Ko-MEFs reduziert ist. Dies deutet 
darauf hin, dass die Expression von CLUH eventuell transkriptional von PGC-1α 
kontrolliert wird. Zusammenfassend können wir schließen, dass unter dem Einfluss des 
zellulären Metabolismus` CLUH wahrscheinlich für die Biogenese seiner Ziel-mRNAs 
wichtig ist. 
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Figure 34 : CLUH overexpression induces different target responses. The two replicates of 
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Symbol FoldChange pValue Description 
ABAT 13,71 0,000008 4-aminobutyrate aminotransferase  
ABCB10 5,88 0,000001 ATP-binding cassette, sub-family B (MDR/TAP), member 10  
ABCB7 25,24 0,000001 ATP-binding cassette, sub-family B (MDR/TAP), member 7  
ABCB8 24,04 0,000001 ATP-binding cassette, sub-family B (MDR/TAP), member 8 
ABHD10 9,94 0,000001 abhydrolase domain containing 10 
ABHD11 12,4 0,000001 abhydrolase domain containing 11 
ACAA2 9,79 0,000001 acetyl-CoA acyltransferase 2  
ACAD10 9,61 0,000003 acyl-CoA dehydrogenase family, member 10  
ACAD8 16,44 0,000001 acyl-CoA dehydrogenase family, member 8  
ACAD9 5,41 0,000001 acyl-CoA dehydrogenase family, member 9  
ACADL 21,07 0,000001 acyl-CoA dehydrogenase, long chain  
ACADM 35,22 0,000001 acyl-CoA dehydrogenase, C-4 to C-12 straight chain  
ACADS 21,69 0,000001 acyl-CoA dehydrogenase, C-2 to C-3 short chain  
ACADSB 6,65 0,000001 acyl-CoA dehydrogenase, short/branched chain 
ACADVL 6,15 0,000001 acyl-CoA dehydrogenase, very long chain  
ACAT1 17,3 0,000001 acetyl-CoA acetyltransferase 1  
ACO2 19,17 0,000001 aconitase 2, mitochondrial  
ACOT2 9,34 0,000001 acyl-CoA thioesterase 2 
ACSF2 32,86 0,000001 acyl-CoA synthetase family member 2 
ACSF3 7,5 0,000001 acyl-CoA synthetase family member 3 
ACSM3 16,8 0,000001 acyl-CoA synthetase medium-chain family member 3 
ADCK5 7,08 0,000001 aarF domain containing kinase 5  
Table 17. The complet list of genes encoding for NEMPs that are bound by CLUH. Only gene enriched more than 5 times, P≤0.01 were analysed 
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AGK 10,69 0,000001 acylglycerol kinase  
AGMAT 23,1 0,000001 agmatine ureohydrolase (agmatinase)  
AIFM1 28,76 0,000001 apoptosis-inducing factor, mitochondrion-associated, 1 
ALAS1 30,99 0,000001 aminolevulinate, delta-, synthase 1 
ALDH18A1 34,22 0,000001 aldehyde dehydrogenase 18 family, member A1 
ALDH1B1 11,16 0,000001 aldehyde dehydrogenase 1 family, member B1  
ALDH1L2 17,73 0,000001 aldehyde dehydrogenase 1 family, member L2  
ALDH2 20,13 0,000001 aldehyde dehydrogenase 2 family (mitochondrial)  
ALDH4A1 9,91 0,000001 aldehyde dehydrogenase 4 family, member A1  
ALDH5A1 20,95 0,000001 aldehyde dehydrogenase 5 family, member A1 
ALDH6A1 42,97 0,000001 aldehyde dehydrogenase 6 family, member A1  
ALDH7A1 25,98 0,000001 aldehyde dehydrogenase 7 family, member A1  
ALDH9A1 13,55 0,000001 aldehyde dehydrogenase 9 family, member A1  
AMACR 5,23 0,008462 alpha-methylacyl-CoA racemase  
APEX2 7,26 0,000001 APEX nuclease (apurinic/apyrimidinic endonuclease) 2  
APOO 5,65 0,000001 apolipoprotein O  
ATP5A1 5,85 0,000001 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle  
ATPAF1 12,37 0,000001 ATP synthase mitochondrial F1 complex assembly factor 1  
ATPAF2 37,6 0,000001 ATP synthase mitochondrial F1 complex assembly factor 2  
AUH 13,62 0,000001 AU RNA binding protein/enoyl-CoA hydratase  
AURKAIP1 7,43 0,000001 aurora kinase A interacting protein 1  
BCAT2 16,52 0,000001 branched chain amino-acid transaminase 2, mitochondrial  
BCKDHA 11,77 0,000036 branched chain keto acid dehydrogenase E1, alpha polypeptide  
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BCKDHB 7,93 0,000001 branched chain keto acid dehydrogenase E1, beta polypeptide  
BCKDK 6,09 0,000001 branched chain ketoacid dehydrogenase kinase  
BCO2 10,76 0,000001 beta-carotene oxygenase 2  
BDH1 23,94 0,000001 3-hydroxybutyrate dehydrogenase, type 1  
BPHL 5,12 0,000001 biphenyl hydrolase-like (serine hydrolase)  
C10orf2 10,48 0,000001 chromosome 10 open reading frame 2  
C1QBP 5,18 0,000001 complement component 1, q subcomponent binding protein  
C2orf47 8,54 0,000001 chromosome 2 open reading frame 47  
CARS2 17,23 0,000001 cysteinyl-tRNA synthetase 2, mitochondrial (putative)  
CCDC109B 6,99 0,000001 coiled-coil domain containing 109B  
CCDC51 9,31 0,000001 coiled-coil domain containing 51  
CECR5 10,2 0,000001 cat eye syndrome chromosome region, candidate 5  
CHDH 37,26 0,000001 choline dehydrogenase  
CKMT1B;CKMT1A 24,81 0,000001 creatine kinase, mitochondrial 1A  
CKMT1B;CKMT1A 17,04 0,000001 creatine kinase, mitochondrial 1B  
CLPB ? 21,64 0,000001 ClpB caseinolytic peptidase B homolog (E. coli)  
CLPP 6,57 0,000001 caseinolytic mitochondrial matrix peptidase proteolytic subunit  
CLYBL 7,78 0,000066 citrate lyase beta like  
COQ3 21,46 0,000001 coenzyme Q3 methyltransferase  
COQ6;LOC1027238 19,96 0,000001 coenzyme Q6 monooxygenase  
COX15 18,72 0,000001 cytochrome c oxidase assembly homolog 15 (yeast)  
CPOX 9,5 0,000001 coproporphyrinogen oxidase  
CPS1;LOC1027239 16,36 0,000001 carbamoyl-phosphate synthase 1, mitochondrial  
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CPT2 35,27 0,000001 carnitine palmitoyltransferase 2  
CRAT 5,82 0,000001 carnitine O-acetyltransferase  
D2HGDH 17,76 0,000001 D-2-hydroxyglutarate dehydrogenase  
DARS2 38,23 0,000001 aspartyl-tRNA synthetase 2, mitochondrial  
DBT 9,24 0,000001 dihydrolipoamide branched chain transacylase E2  
DDX28 9,28 0,000001 DEAD (Asp-Glu-Ala-Asp) box polypeptide 28  
DECR1 16,01 0,000001 2,4-dienoyl CoA reductase 1, mitochondrial  
DHODH 5,73 0,000001 dihydroorotate dehydrogenase (quinone)  
DHRS2 21,78 0,000001 dehydrogenase/reductase (SDR family) member 2  
DHTKD1 7,37 0,000001 dehydrogenase E1 and transketolase domain containing 1  
DLAT 36,76 0,000001 dihydrolipoamide S-acetyltransferase  
DLD 24,28 0,000001 dihydrolipoamide dehydrogenase  
DLST 16,2 0,000001 dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)  
DUS2 10,03 0,000001 dihydrouridine synthase 2  
EARS2 5,8 0,000001 glutamyl-tRNA synthetase 2, mitochondrial  
ECH1 5,46 0,000001 enoyl CoA hydratase 1, peroxisomal  
ECHDC3 8,5 0,000001 enoyl CoA hydratase domain containing 3  
ECHS1 23,53 0,000001 enoyl CoA hydratase, short chain, 1, mitochondrial  
ELAC2 12,18 0,000001 elaC ribonuclease Z 2  
ETFA 8,95 0,000001 electron-transfer-flavoprotein, alpha polypeptide  
ETFDH 30,3 0,000001 electron-transferring-flavoprotein dehydrogenase  
FAM210A 5,21 0,000001 family with sequence similarity 210, member A 
FARS2 5,38 0,000001 phenylalanyl-tRNA synthetase 2, mitochondrial  
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FASTKD1 8,69 0,000001 FAST kinase domains 1  
FASTKD5 6,28 0,000001 FAST kinase domains 5  
FECH 9,11 0,000001 ferrochelatase 
FH 17,81 0,000001 fumarate hydratase 
FOXRED1 5,7 0,000001 FAD-dependent oxidoreductase domain containing 1 
FTSJ2 6,76 0,000001 FtsJ RNA methyltransferase homolog 2 (E. coli)  
FXN 10,58 0,000001 frataxin  
GATB 11,02 0,000001 glutamyl-tRNA(Gln) amidotransferase, subunit B  
GATM;102724493 17,68 0,000001 glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
GBAS 25,24 0,000001 glioblastoma amplified sequence  
GFM1 57,35 0,000001 G elongation factor, mitochondrial 1  
GFM2 21,65 0,000001 G elongation factor, mitochondrial 2 
GHITM 37,78 0,000001 growth hormone inducible transmembrane protein  
GLDC 22,19 0,000001 glycine dehydrogenase (decarboxylating)  
GLRX2 5,33 0,000001 glutaredoxin 2  
GLS 12,8 0,000001 glutaminase  
GLUD1 9,55 0,000001 glutamate dehydrogenase 1  
GPT2 11,75 0,000001 glutamic pyruvate transaminase (alanine aminotransferase) 2 
GTPBP3 6,79 0,000001 GTP binding protein 3 (mitochondrial)  
GUF1;LOC1027253 6,22 0,000001 GUF1 GTPase homolog (S. cerevisiae)  
HADHA 21,13 0,000001 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), alpha subunit  
HADHB 18,15 0,000001 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), beta subunit  
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HIBADH 43,97 0,000001 3-hydroxyisobutyrate dehydrogenase  
HSCB 9,99 0,000001 HscB mitochondrial iron-sulfur cluster co-chaperone  
HSPA9 37,77 0,000001 heat shock 70kDa protein 9 (mortalin)  
HSPD1 14,84 0,000001 heat shock 60kDa protein 1 (chaperonin)  
IARS2 31,17 0,000001 isoleucyl-tRNA synthetase 2, mitochondrial  
IBA57 6,96 0,000001 IBA57, iron-sulfur cluster assembly homolog (S. cerevisiae)  
IDH2 11,02 0,000001 isocitrate dehydrogenase 2 (NADP+), mitochondrial  
IMMT 26,16 0,000001 inner membrane protein, mitochondrial  
IVD 5,72 0,000001 isovaleryl-CoA dehydrogenase  
KIAA0141 11,16 0,000001 KIAA0141 
KIAA0391 8,43 0,000001 KIAA0391  
L2HGDH 19,56 0,000001 L-2-hydroxyglutarate dehydrogenase 
LACTB 41,1 0,000001 lactamase, beta  
LACTB2 7,53 0,000001 lactamase, beta 2  
LARS2 39,12 0,000001 leucyl-tRNA synthetase 2, mitochondrial  
LDHD 11,61 0,000001 lactate dehydrogenase D  
LETM1 10,78 0,000001 leucine zipper-EF-hand containing transmembrane protein 1  
LONP1 22,66 0,000001 lon peptidase 1, mitochondrial  
LRPPRC 26,04 0,000001 leucine-rich pentatricopeptide repeat containing  
MACROD1 17,33 0,000001 MACRO domain containing 1 
MCAT 9,09 0,000001 malonyl CoA:ACP acyltransferase (mitochondrial)  
MCCC1 14,71 0,000001 methylcrotonoyl-CoA carboxylase 1 (alpha) 
MCCC2 17,9 0,000001 methylcrotonoyl-CoA carboxylase 2 (beta)  
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MDH2 10,46 0,000001 malate dehydrogenase 2, NAD (mitochondrial) 
ME2 11,09 0,000001 malic enzyme 2, NAD(+)-dependent, mitochondrial  
ME3 7,06 0,000001 malic enzyme 3, NADP(+)-dependent, mitochondrial  
MECR 7,04 0,000001 mitochondrial trans-2-enoyl-CoA reductase  
METTL17 6,47 0,000001 methyltransferase like 17  
MICU1 9,21 0,000001 mitochondrial calcium uptake 1  
MIPEP 12,12 0,000001 mitochondrial intermediate peptidase  
MMAA 8,54 0,000025 methylmalonic aciduria (cobalamin deficiency) cblA type  
MRPL13 8,03 0,000001 mitochondrial ribosomal protein L13  
MRPL16 33,05 0,000001 mitochondrial ribosomal protein L16  
MRPL22 7,64 0,000001 mitochondrial ribosomal protein L22  
MRPL30 12,85 0,000001 mitochondrial ribosomal protein L30  
MRPL39 12,33 0,000001 mitochondrial ribosomal protein L39  
MRPL4 5,91 0,000001 mitochondrial ribosomal protein L4  
MRPL44 8,93 0,000001 mitochondrial ribosomal protein L44  
MRPS11 5,7 0,000001 mitochondrial ribosomal protein S11  
MRPS14 5,88 0,000001 mitochondrial ribosomal protein S14  
MRPS15 7,23 0,000001 mitochondrial ribosomal protein S15  
MRPS2 5 0,000001 mitochondrial ribosomal protein S2  
MRPS26 5,78 0,000001 mitochondrial ribosomal protein S26 
MTERF2 6,08 0,000001 mitochondrial transcription termination factor 2 
MTERF3 6,7 0,000001 mitochondrial transcription termination factor 3  
MUT 29,64 0,000001 methylmalonyl CoA mutase  
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NADK2 12,25 0,000001 NAD kinase 2, mitochondrial  
NDUFA10 10,19 0,000001 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa  
NDUFA9 8,05 0,000001 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa  
NDUFAB1 20,76 0,000001 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8kDa  
NDUFAF5 9,67 0,000001 NADH dehydrogenase (ubiquinone) complex I, assembly factor 5  
NDUFAF7 7,12 0,000001 NADH dehydrogenase (ubiquinone) complex I, assembly factor 7  
NDUFS1 17,96 0,000001 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-coenzyme Q reductase)  
NDUFS2 11,62 0,000001 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q reductase)  
NDUFS7 6,23 0,000001 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q reductase) 
NDUFV1 17,6 0,000001 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa  
NFS1 18,77 0,000001 NFS1 cysteine desulfurase 
NIPSNAP1 5,64 0,000001 nipsnap homolog 1 (C. elegans)  
NLRX1 5,89 0,000001 NLR family member X1  
NNT 30,93 0,000001 nicotinamide nucleotide transhydrogenase  
NUBPL 6,44 0,000001 nucleotide binding protein-like  
NUDT13 5,38 0,00004 nudix (nucleoside diphosphate linked moiety X)-type motif 13  
NUDT6 6,05 0,000176 nudix (nucleoside diphosphate linked moiety X)-type motif 6  
OAT 8,86 0,000001 ornithine aminotransferase  
OGDH 41,06 0,000001 oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)  
OGDHL 8,56 0,000001 oxoglutarate dehydrogenase-like  
OMA1 19,09 0,000001 OMA1 zinc metallopeptidase  
OPA1 23,49 0,000001 optic atrophy 1 (autosomal dominant)  
OXA1L 5,53 0,000001 oxidase (cytochrome c) assembly 1-like  
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OXCT1 20,66 0,000001 3-oxoacid CoA transferase 1  
PARS2 12,65 0,000001 prolyl-tRNA synthetase 2, mitochondrial (putative) 
PC 41,85 0,000001 pyruvate carboxylase  
PCCA 57,35 0,000001 propionyl CoA carboxylase, alpha polypeptide  
PCCB 15,94 0,000001 propionyl CoA carboxylase, beta polypeptide 
PCK2 16,37 0,000001 phosphoenolpyruvate carboxykinase 2 (mitochondrial)  
PDE12 6,68 0,0016 phosphodiesterase 12  
PDF 5,47 0,000001 peptide deformylase (mitochondrial)  
PDHA1 13,67 0,000001 pyruvate dehydrogenase (lipoamide) alpha 1  
PDHB 17 0,000001 pyruvate dehydrogenase (lipoamide) beta  
PDHX 8,56 0,000001 pyruvate dehydrogenase complex, component X  
PDSS2 22,06 0,000001 prenyl (decaprenyl) diphosphate synthase, subunit 2  
PINK1 39,82 0,000001 PTEN induced putative kinase 1  
PITRM1 26,94 0,000001 pitrilysin metallopeptidase 1  
PMPCA 38,73 0,000001 peptidase (mitochondrial processing) alpha  
PNPT1;LOC102723 11,75 0,000001 polyribonucleotide nucleotidyltransferase 1  
POLDIP2 8,81 0,000001 polymerase (DNA-directed), delta interacting protein 2  
PPA2 37,06 0,000001 pyrophosphatase (inorganic) 2  
PPIF 10,34 0,000001 peptidylprolyl isomerase F  
PPOX 5,29 0,000001 protoporphyrinogen oxidase  
PRDX3 12,74 0,000001 peroxiredoxin 3  
PUS1 5,84 0,000001 pseudouridylate synthase 1  
PYROXD2 10,5 0,000001 pyridine nucleotide-disulphide oxidoreductase domain 2  
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RNMTL1 7,67 0,000001 RNA methyltransferase like 1  
SCO1 8,15 0,000001 SCO1 cytochrome c oxidase assembly protein  
SDHA 31,02 0,000001 succinate dehydrogenase complex, subunit A, flavoprotein (Fp)  
SDHB 6,9 0,000001 succinate dehydrogenase complex, subunit B, iron sulfur (Ip)  
SDHC 5,03 0,000001 succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa 
SDHD 6,41 0,000001 succinate dehydrogenase complex, subunit D, integral membrane protein  
SPG7 8,07 0,000001 spastic paraplegia 7 (pure and complicated autosomal recessive)  
SPRYD4 7,96 0,000001 SPRY domain containing 4  
SUGCT 19,55 0,000001 succinyl-CoA:glutarate-CoA transferase  
SUOX 9,7 0,000001 sulfite oxidase  
TARS2;MIR6878 11,85 0,000001 threonyl-tRNA synthetase 2, mitochondrial (putative)  
TFAM 6,14 0,000001 transcription factor A, mitochondrial  
TFB2M 6,39 0,000001 transcription factor B2, mitochondrial 
THNSL1 20,72 0,000001 threonine synthase-like 1 (S. cerevisiae)  
TIMM21 8,03 0,000001 translocase of inner mitochondrial membrane 21 homolog (yeast)  
TK2 5,52 0,000001 thymidine kinase 2, mitochondrial  
TMEM143 9,11 0,000001 transmembrane protein 143 
TMEM177 5,65 0,000001 transmembrane protein 177  
TMEM186 9,62 0,000001 transmembrane protein 186  
TMEM70 6,74 0,000001 transmembrane protein 70  
TMLHE 13,09 0,000001 trimethyllysine hydroxylase, epsilon  
TRMT10C 17,21 0,000001 tRNA methyltransferase 10 homolog C (S. cerevisiae)  
TRNT1 6,96 0,000001 tRNA nucleotidyl transferase, CCA-adding, 1  
  






TRUB2 15,49 0,000001 TruB pseudouridine (psi) synthase family member 2  
TSFM 10,9 0,000001 Ts translation elongation factor, mitochondrial 
TST 6,35 0,000001 thiosulfate sulfurtransferase (rhodanese)  
TXNRD2 20,87 0,000001 thioredoxin reductase 2  
UNG 5,22 0,000001 uracil-DNA glycosylase  
UQCRC2 5,29 0,000001 ubiquinol-cytochrome c reductase core protein II  
UQCRFS1 8,03 0,000001 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 
VWA8 11,64 0,000001 von Willebrand factor A domain containing 8  
WBSCR16 19,77 0,000001 Williams-Beuren syndrome chromosome region 16  
XPNPEP3 5,61 0,000001 X-prolyl aminopeptidase (aminopeptidase P) 3, putative 
ZADH2 8,7 0,000001 zinc binding alcohol dehydrogenase domain containing 2  
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List of Abbreviations 
 
Abbreviation Full name 
µCi Microcurie 




CLIP Crosslinking immunoprecipitation 
CLUH Clustered mitochondria (cluA/CLU1) homolog 
DMEM Dulbecco's Modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DPBS Dulbecco's Phosphate-Buffered Saline 
g earth gravitational acceleration 
HEK Human embryonal kidney cell 
kDa Kilo dalton 
M Molar 
mA Miliamper 




mtDNA Mitochondrial DNA 
NEMP Nuclear encoded mitochondrial protein 
nM Nanomolar 
OPA1 Optic Atrophy 1 
OXPHOS Oxidative Phosphorylation 
PBS Phosphate buffer saline 
PINK1 PTEN Induced Putative kinase 
PNK Polynucleotide Kinase 
RIPA buffer Radioimmunoprecipitation assay buffer 
RNP Ribonucleoprotein 
RT Room temperature 
s Second  
siRNA Small interfering RNA 
TCA Trichloroacetic Acid 
WT Wildtype 
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